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ABSTRACT 
 
During the 20th century, significant strides were made in curtailing the burden of 
childhood diarrhea, including advances in vaccine research, the advent of antibiotics, improved 
water and sanitation, and expanded access to health information across the globe. Despite this 
progress, today diarrhea ranks second only to pneumonia as a leading cause of mortality in 
children under five years, with a disproportionate burden of 90% of diarrheal deaths in South 
Asia and Sub-Saharan Africa. Additionally, substantial morbidity due to diarrhea persists in 
young children, with more than 45 million disability-adjusted life years (DALYs) lost due to 
diarrhea in 2015. Long-term consequences of childhood diarrhea include undernutrition, impaired 
gut function, altered gut microbiota, and compromised cognitive development.  
 
The 21st century presents an opportunity to eliminate the health disparity affecting 
millions of children suffering disproportionately from preventable diarrheal diseases. Recent 
advances in molecular laboratory technology have enabled detailed assessment of diarrheal 
burden and etiology, illuminating the highest burden pathogens for focused interventions. Among 
the top diarrheal pathogens, rotavirus (RV) is the leading cause of diarrhea-attributable death in 
the first year of life. While we have vaccines against RV, these vaccines consistently 
underperform in low and middle-income countries (LMICs) with efficacy of 18% to 61% 
compared to > 85% efficacy in high income countries. Reasons for rotavirus vaccine 
underperformance remain unclear, and no vaccines are available for other high burden diarrheal 
pathogens. This requires consideration of complementary and alternative interventions for 
diarrhea prevention. 
 
To assess factors related to rotavirus vaccine performance, we enrolled a 700-infant birth 
cohort in an urban slum of Dhaka, Bangladesh, in the Performance of Rotavirus and Oral Polio 
Vaccines in Developing Countries (PROVIDE) study: a randomized controlled trial of a 2-dose 
monovalent oral rotavirus vaccine (RV1). With a primary outcome of any rotavirus diarrhea 
(RVD) post-vaccination to one year, we conducted biweekly home-based diarrhea surveillance 
with rotavirus antigen detection in diarrheal stools by ELISA. We found RV1 efficacy of 51% 
(95% CI 33.8–63.7) in per protocol analysis. Importantly, among 12 explanatory variables tested 
for association with RVD, serum zinc concentration (SZC) in infants at week 18 associated with 
risk of RVD up to one year (OR 0.77, 95% CI 0.66–0.91), independent of vaccination status. This 
finding led to broader investigation of the relationship between zinc status and diarrhea in the 
PROVIDE cohort. 
 
Among 577 PROVIDE infants, 16.5% were zinc deficient at week 18 (SZC < 65μg/dL). 
By logistic regression, zinc deficient infants had increased odds of diarrhea in the first year of life 
compared to zinc replete infants (OR 2.76, 95% CI 1.08–7.04), and they were nearly 4 times 
more likely to have diarrhea of viral etiology (OR 3.94, 95% CI 1.55–10.03). Furthermore, in 
Kaplan Meier analysis we found a strong correlation between zinc deficiency and time to first 
episode of viral diarrhea (median survival 27 vs 33 weeks in zinc deficient vs non-deficient 
infants, p  <0.0001), with zinc deficient infants at 55% greater risk of viral diarrhea (HR 1.55, 
95% CI 1.21 – 1.99).   
 
 Our results indicate further consideration of zinc as a critical and modifiable co-factor 
in ameliorating the burden of childhood viral diarrhea. Carefully designed trials of zinc 
supplementation interventions could determine whether zinc may fill the gap in protection against 
childhood viral diarrhea, and inquiries into the zinc-diarrhea molecular pathway could elucidate 
mechanisms for focused development of future interventions. 
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CHAPTER 1: REVIEW OF THE EPIDEMIOLOGY, ETIOLOGY AND 
POTENTIAL PREVENTIVE INTERVENTIONS FOR CHILDHOOD DIARRHEA 
IN LOW AND MIDDLE INCOME COUNTRIES 
 
1.1.  Introduction 
During the 20th century, significant strides were made in curtailing the burden of 
childhood diarrhea, including advances in vaccine research, the advent of antibiotics, 
improved water and sanitation, and expanded access to health information across the 
globe. Despite this progress, today over half a million children die from diarrhea-
associated complications before their fifth birthday [1]; almost all of them in South Asia 
and Sub-Saharan Africa. The 21st century presents an opportunity to incorporate past 
successes with cutting-edge basic science and excellent clinical research to drive our 
understanding and elimination of the persistent public health challenge of childhood 
diarrhea. 
 
To that end, the objective of this review is to identify optimal preventive interventions to 
address the health disparity affecting millions of children suffering disproportionately 
from preventable diarrheal diseases. This work constitutes a fully translational inquiry 
beginning with a review of the global epidemiology of childhood diarrheal morbidity and 
mortality, including our recently expanded understanding of diarrheal burden and 
etiology. This brings into sharp relief questions about effective prevention strategies 
against lead diarrheal pathogens. Review of currently available diarrhea interventions 
follows, with particular emphasis on zinc for diarrhea prevention based on results from 
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original research in Bangladesh on rotavirus vaccine efficacy (Chapter 2), which led to 
observations correlating zinc deficiency with increased risk of viral diarrhea (Chapter 3). 
Review of the zinc literature culminates with hypotheses on the molecular mechanisms 
involved in the zinc-diarrhea pathway and evaluation of evidence on the effectiveness of 
zinc supplementation for diarrhea prevention. The review ends with discussion of 
unanswered questions and future directions. 
 
1.2.  Epidemiology of childhood diarrhea 
In 2000, the global community set ambitious priorities for ameliorating poverty and 
public health disparities in the 21st century with the declaration of the United Nations’ 
(UN) Millennium Development Goals. One of the eight targets agreed by UN member 
states was a two-thirds reduction in child mortality by 2015. This goal brought into focus 
the leading causes of mortality in children under 5 years, among which diarrhea ranks 
second only to pneumonia in the post-neonatal period [2]. Diarrhea-attributable mortality 
can result from either acute or chronic diarrhea, with dehydration and malnutrition as the 
immediate cause of death from each condition, respectively.  
 
Despite significant progress, the target reduction in child mortality is yet to be met, with 
overall deaths declining one third from 9.9 million in 2000 to 6.3 million in 2013. 
Diarrhea-attributable mortality has decreased at an annual rate of reduction of 6.5% since 
2000; however diarrhea still accounts for over half a million child deaths annually, with a 
disproportionate burden of 90% of diarrheal mortality in South Asia and Sub-Saharan 
Africa [1-3], as shown in Figure 1.1..  
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Figure 1.1. Disproportionate burden of diarrheal mortality in South Asia and Sub-Saharan Africa, 
2015 (From: Global Burden of Diseases Diarrhoeal Diseases Collaborators [3])  
 
In addition to the challenge of reducing diarrhea-attributable mortality, substantial 
morbidity due to diarrhea persists in young children. Recent analysis estimates more than 
45 million disability-adjusted life years (DALYs) lost due to diarrhea and approximately 
one billion episodes of diarrhea in children under 5 in 2015 [3]. Again, this burden falls 
disproportionately on children in South Asia and Sub-Saharan Africa. Diarrheal 
incidence decreased more slowly than mortality over the past few decades, with a 
reduction from 3.4 to 2.9 episodes per child-year between 1990 and 2010 [4].  
 
The long-term consequences of childhood diarrhea are just beginning to be understood 
and include undernutrition (linear growth faltering and underweight), impaired gut 
function, dysregulation of inflammatory and immune responses, altered microbiota, and 
compromised cognitive development [5-8]. Collectively, these sequelae contribute to 
decreased productivity and poor health outcomes into adulthood. 
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1.2.1. Epidemiology of viral diarrhea 
Very little has been published on the epidemiology of viral diarrhea as a discrete 
etiology. Diarrheas of viral etiology share a few key features. First, viral diarrhea knows 
no boundaries. Rotavirus, the leading cause of childhood diarrhea globally (see below), 
accounted for the highest burden of childhood diarrhea in the United States and other 
high income countries (HICs) prior to vaccine introduction in the 2000’s [9]. Similarly, 
other top viral pathogens are found to cause diarrhea across the globe, regardless of 
national income or infrastructure. Diarrheal viruses tend to infect humans early in life, 
with the highest rates of viral diarrhea due to rotavirus, adenovirus, norovirus, sapovirus 
and astrovirus all occurring in children < 2 years [9]. Clinically, viral diarrheas are often 
grouped together as relatively short duration and self-limiting; these clinical observations 
from HICs may not be relevant in LMICs where children develop under different living 
conditions and may be pre-disposed to longer duration, greater severity or increased risk 
of viral diarrhea.   
 
1.3.  Etiology of diarrhea 
In order to identify optimal interventions to address the continued burden of diarrheal 
morbidity and mortality, scientists recognized the need to better understand the etiology 
of childhood diarrhea, particularly in low and middle-income countries (LMICs). To this 
end, two landmark, multi-site studies were conducted between 2007–2014, enrolling over 
24,000 children across 12 countries in South Asia, Africa and South America: the Global 
Enteric Multicenter Study (GEMS), and the Malnutrition and Enteric Disease Study 
(MAL-ED). GEMS was a case-control study of moderate-to-severe diarrhea in children 
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age 1-59 months, while MAL-ED was a longitudinal birth cohort with community-based 
diarrheal detection (i.e. milder cases) in which children were enrolled at birth and 
followed for 2 years including collection of both diarrheal and asymptomatic stools. 
Despite different study designs, the top pathogens contributing to attributable incidence 
of diarrhea in GEMS and MAL-ED were similar, particularly in the first year of life.  
 
Statistical methods for determining attributable incidence in GEMS and MAL-ED are 
extensively detailed elsewhere [10, 11], and include first estimation of pathogen-specific 
attributable fractions by Quantification Cycle (Cq) read-outs from quantitative 
polymerase chain reaction (PCR) TaqMan Array Card (TAC) assay (detailed below). 
Attributable fractions per pathogen were adjusted for prevalence of asymptomatic 
carriage by odds of detection in cases vs controls, Cq value, quantity of co-pathogens, 
study site, age and sex. Attributable incidence was then calculated from attributable 
fraction estimates based on previous methods [12]. 
 
Rotavirus (RV) accounted for the highest attributable incidence of diarrhea during 
infancy in all study sites where RV vaccines had not been introduced, and RV remained 
the fifth leading cause of diarrhea in countries with RV vaccines [10, 11]. This aligns 
with estimates from the World Health Organization’s (WHO) Global Rotavirus 
Surveillance Network that approximately 40% of hospitalizations for acute diarrhea in 
children under 5 in LMICs are due to rotavirus [13].  
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Although the GEMS and MAL-ED studies showed some geographic heterogeneity in 
pathogen prevalence, other important diarrheal agents in the first year of life were 
adenovirus 40/41, Shigella spp, Campylobacter spp, heat-stable enterotoxigenic E. coli 
(ST-ETEC), and Cryptosporidium spp.  In GEMS, 77.8% of attributable diarrhea was due 
to RV and these five pathogens [10]. Notably, in MAL-ED, norovirus GII was the highest 
burden diarrheal pathogen in countries with RV vaccine, a trend also seen in the United 
States after introduction of RV vaccines in 2006 when norovirus GII replaced rotavirus as 
the leading cause of acute gastroenteritis in children [1, 14]. 
 
1.3.1. Next generation diagnostic tools 
The findings in both the GEMS and MAL-ED studies were facilitated by a next 
generation molecular laboratory assay, the quantitative polymerase chain reaction (PCR) 
TaqMan Array Card (TAC). TAC originated as a tool for gene expression studies and 
was adapted for detection of respiratory and bioterror pathogens in 2010-2012. In 2012, 
the assay was developed for stool-based enteropathogen detection at the University of 
Virginia [15]. The TAC platform consists of a set of individual, microbe-specific, probe-
based assays assembled on a single card for simultaneous nucleic acid detection of 
multiple pathogens per stool sample for up to 42 pathogen targets per card at present. The 
assay read-out is a quantification cycle value (Cq) indicating the amplification cycle 
number at which flouresced pathogen-specific nucleic acid is detectable above 
background. Similar to CT values for other PCR-based platforms, the positive detection 
range for TAC Cq has been established as 0 < Cq < 35 based on comparator studies with 
conventional and other PCR methods [15, 16]. 
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The TAC assay addresses some of the shortcomings of conventional lab methods for 
pathogen detection (i.e. culture, microscopy, ELISA and PCR), including: time and cost 
associated with multiple tests on individual stools, limited comparability across sites 
using different detection methods for specific pathogens, risk of contamination of 
specimens or assays when moving between platforms, and most importantly, poor 
sensitivity for detection of several diarrheal pathogens. The TAC assay has undergone 
extensive optimization and validation across international sites, as well as head-to-head 
comparisons for pathogen-specific specificity and sensitivity compared to conventional 
methods [16, 17]. Importantly, with the exception of ELISA for rotavirus detection, 
conventional methods generally showed poor sensitivity and similar specificity compared 
to TAC [16].  
 
The TAC assay has limitations. Notably, near the TAC assay’s lower limit of detection 
(Cq = 30-35) the odds ratios of pathogen detection in cases vs controls approaches 1 for 
most pathogens, possibly indicating less clinically meaningful results at this end of the 
detection range [16]. In this case, an odds ratio of 1 indicates no difference between cases 
and controls, while an odds ratio < 1 suggests greater pathogen carriage in children 
without overt diarrhea (controls). Additionally, with all pathogen targets assembled on a 
single card, re-running a whole card for repeat tests of individual pathogens is relatively 
expensive, and back-up conventional methods for single-pathogen repeats are necessary. 
Finally, for labs without PCR capacity, substantial initial investment in a PCR platform is 
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required, though once established, TAC is less expensive per specimen compared to 
running multiple conventional methods.  
 
As applied to the GEMS and MAL-ED studies, TAC has illuminated two important 
aspects of diarrheal disease previously obscured by conventional lab methods. First, due 
to its high sensitivity (median 90.2% [IQR 84.2 – 95.1]), TAC detected a high prevalence 
of enteric co-infections in both diarrheal and control specimens [16]. For example, in 
GEMS, ≥ 2 pathogens were detected at diarrhea-associated Cq values in nearly 40% of 
diarrheal stools (e.g. low Cq indicating high pathogen load with an odds ratio > 1 for 
detection in cases vs controls). This finding revolutionizes our understanding of diarrheal 
etiology, moving us past the model of single-pathogen diarrhea causation. Secondly, 
analytic methods applied to TAC data suggest high levels of subclinical carriage of many 
pathogens in controls based on the odds of pathogen presence in diarrheal vs control 
specimens [10, 16].   
 
These findings challenge the field to define a clinically-meaningful TAC Cq cut-off for 
each pathogen that associates with diarrhea, and to grapple with the biologic relevance 
and consequences of 1) multiple pathogens present at diarrhea-associated levels per stool 
(how do we determine attribution?), and 2) the substantial prevalence of pathogenic 
microbes found in children without overt diarrhea. Interpretation of TAC data and the 
biologic implications of TAC findings is a work-in-progress, but this new tool has 
already boosted our understanding of the complexity of diarrheal disease in the 21st 
century. 
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1.4. Prevention of diarrhea 
Armed with a better understanding of diarrheal etiology and the complex mix of co-
infections in which pathogen exposure either does or does not lead to diarrhea, we turn to 
the question of prevention. How do we leverage emerging knowledge and tools to 
address the persistent burden of childhood diarrheal morbidity and mortality in LMICs? 
Table 1.1. summarizes the current prevention (vaccines) and treatment options for the top 
seven diarrhea-associated pathogens among infants in LMICs. 
Table 1.1. Summary of prevention and treatment options for key pathogens                
(immunocompetent infants) 
Pathogen Pathogen Class Transmission route 
Licensed 
vaccine(s)? Treatment options 
Rotavirus Virus Fecal-oral 
 
Possibly respiratory 
(limited evidence [18]) 
Yes, with 
18-61% 
efficacy in 
LMICs 
ORS and zinc 
Norovirus GII Virus Fecal-oral No ORS and zinc 
Adenovirus 40/41 Virus Fecal-oral No ORS and zinc 
Campylobacter spp Bacteria Fecal-oral No ORS and zinc 
Fluoroquinolone and 
azithromycin, antibiotic 
resistance is common 
(severe disease only) 
Shigella spp/EIEC Bacteria Fecal-oral No ORS and zinc 
Fluoroquinolone and 
azithromycin, antibiotic 
resistance is common 
ST-ETEC Bacteria Fecal-oral No ORS and zinc 
Fluoroquinolones 
Cryptosporidium Parasite Fecal-oral  
Zoonosis 
No ORS 
Nitazoxanide 
Abbreviations: spp=species; EIEC=Enteroinvasive Escherichia coli; ST-ETEC=Enterotoxigenic Escherichia coli; 
ORS=oral rehydration solution. 
Table compiled from pathogen-specific information available from the Centers for Disease Control and Prevention 
(CDC) [19] 
 
Our focus is on prevention of diarrhea, as opposed to treatment, particularly given the 
limited treatment options against viral enteropathogens and the problematic development 
of antimicrobial resistance against antibiotics for the leading causes of bacterial diarrhea 
in LMICs (an issue beyond the scope of this inquiry), as indicated in Table 1.1.. 
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1.5. Vaccines for diarrhea prevention 
Rotavirus (RV) is the only leading diarrheal pathogen for which licensed vaccines are 
currently available. Vaccine development for Shigella spp, ST-ETEC, Campylobacter, 
and norovirus is ongoing, though no vaccine candidates are near licensure [14, 20]. 
Significant challenges to vaccine development remain for adenovirus 40/41 and 
Cryptosporidium spp, and vaccines for these enteric pathogens are not under clinical 
investigation. 
 
1.5.1. Rotavirus vaccines 
Given the high relative contribution of RV to diarrheal morbidity and mortality in 
infancy, substantial efforts focused on RV vaccine development in the 1990s. To date, 
five live, oral RV vaccines have been licensed, and two are pre-qualified by the WHO 
and available in over 100 countries: Rotarix™ (RV1) and Rotateq® (RV5). Several other 
live, oral RV vaccines are under development, as well as next generation inactivated 
parenteral and subunit vaccines (subunit vaccines consist of viral protein fragments, as 
opposed to whole virus) [21, 22].  
 
In high-income countries (HICs), where RV was the leading cause of childhood diarrhea 
prior to vaccine introduction in the mid-2000’s, RV1 and RV5 demonstrated efficacy 
exceeding 95% against severe RV gastroenteritis [23, 24]. Following vaccine 
introduction in the US in 2006, hospitalizations for RV decreased by up to 94%, and the 
Centers for Disease Control and Prevention (CDC) reported up to 89.9% declines in 
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laboratory detection of RV compared to pre-vaccination years [25, 26]. Furthermore, cost 
savings from reductions in health care utilization for RV gastroenteritis in the four years 
following vaccine introduction (2007-2011) were estimated at $924 million. Vaccine 
effectiveness studies have shown sustained protection against RV hospitalizations in 
HICs using RV vaccines [27]. 
 
In contrast, efficacy and effectiveness of the same oral RV vaccines ranges from 18─61% 
in LMICs, leaving a gap in vaccine protection against the highest-burden diarrheal 
pathogen, for reasons that remain unclear [28-31]. Further complicating interpretation of 
low vaccine efficacy, assessment of the standard immunogenicity measure for RV 
vaccines, anti-RV IgA, has found mixed results for correlation with vaccine efficacy in 
LMICs [32-35]. For example, RV vaccine efficacy trials in Malawi and South Africa 
found only 43.6% of the vaccine group (treatment) effect explained by post-vaccination 
RV IgA seropositivity [34]. Additionally, post-vaccination IgA seroconversion and 
geometric mean concentrations among infants in countries with high child mortality rates 
(LMICs) fall significantly below those of vaccinated infants in countries with low child 
mortality (HICs): 53% vs 87% and 47 U/mL vs 236 U/mL respectively [35]. 
Determination of improved correlates of protection for RV is currently underway in our 
research group.    
 
Substantial research efforts by our team and others have aimed to identify factors that 
explain RV vaccine underperformance in LMICs, including: maternal breast milk and 
transplacental RV antibody inhibiting vaccine take [36-38]; delayed dosing of RV 
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vaccine to improve immune responses [39, 40]; RV strain diversity and homotypic vs 
heterotypic vaccine protection [41]; RV seasonality and timing of vaccine dosing [42]; 
co-administration of oral polio vaccine and its effect on RV vaccine immunogenicity [43, 
44]; and systemic inflammation association with reduced RV vaccine immunogenicity 
[6]. Additional recent studies have found associations between histo-blood group antigen 
polymorphisms (Lewis and secretor status) and risk of RV diarrhea, and microbiome 
composition correlations with RV vaccine immunogenicity [45-48]. While these studies 
offer insight into aspects of this complex problem, considerably more work must be done 
to identify discrete factors that, collectively or individually, explain RV vaccine 
performance. 
 
Despite the remaining questions around RV vaccine efficacy in LMICs, the global 
community, supported by the WHO and the Global Alliance for Vaccines and 
Immunizations (GAVI), are proceeding with global roll-out of the currently licensed oral 
RV vaccines on the premise that protection of ~50% is better than none, particularly in 
countries with high diarrhea-attributable child mortality [49]. Given that RV is the 
highest burden diarrheal pathogen in countries without the vaccines, vaccine roll-out can 
be expected to have a substantial impact on diarrheal morbidity and mortality; however, a 
significant gap remains in protection requiring consideration of complementary 
interventions.  
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1.6. Non-vaccine diarrhea prevention measures 
Given that RV is the only high-burden pathogen for which licensed vaccines are 
available, as well as the efficacy issues with RV vaccines raised above, what other 
preventive interventions may contribute to the goal of reducing childhood diarrheal 
morbidity and mortality? Decades of public health research have tried to address this 
question, with three interventions consistently mentioned in the literature on diarrhea 
prevention: 1) household-level improvements in water, sanitation and hand washing; 2) 
promotion of exclusive breastfeeding; and 3) micronutrient supplementation, specifically 
zinc and vitamin A.   
 
1.6.1. WASH interventions 
The axiom that improved water, sanitation and handwashing (WASH) ameliorates 
diarrheal burden has persisted; however, recent evidence challenges this canon. Pickering 
et al found no difference in diarrhea prevalence in children from cluster-randomized 
villages with and without a community-led total sanitation intervention [50]. Baker et al, 
reporting on handwashing practices among caregivers in the GEMS study, found no 
difference in the incidence of diarrhea among children whose caregivers washed their 
hands with soap vs water and ash [51]. In the case of RV, the field has long rejected a 
significant role for WASH in risk of RV diarrhea due to the ubiquitous prevalence of RV 
in HICs with improved sanitation prior to vaccine introduction [18, 27]. We are awaiting 
the results of the multi-site WASH Benefits trial enrolling a birth cohort of nearly 14,000 
children in Kenya and Bangladesh with a primary outcome of diarrhea across six 
randomization arms with different sets of WASH interventions [52]. Interesting 
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hypotheses to pursue with next generation tools such as TAC would be whether the 
effectiveness of WASH interventions is pathogen-specific, if there is greater impact on 
bacterial diarrhea vs viral diarrhea, and whether success of WASH interventions 
associates with inoculum size or pathogen mode of transmission (i.e. waterborne 
transmission is more likely addressed by WASH interventions). 
 
1.6.2. Promotion of exclusive breastfeeding 
The benefits of exclusive breastfeeding (EBF) have been well characterized and reviewed 
numerous times [53]. In short, infants, particularly in the first 6 months of life, have 
immature and developing immune systems. During this period, breast milk not only 
provides essential fats and micronutrients for survival and optimal growth, but also 
transfers immune components, specifically IgA, to protect the infant during immune 
maturation. As reviewed by Duijts et al, interventional and observational studies in high 
income countries consistently found reduced risk of diarrheal disease with increased 
duration of exclusive breastfeeding, often in a dose-dependent manner with each 
additional month of exclusive breastfeeding [54]. Similar to other studies, results from 
the Southhampton Women’s Survey showed a relative risk of diarrhea from birth to 6 
months of RR 0.43 (95% CI 0.30–0.61) in infants breastfed for 6+ months vs those never 
breastfed [55]. In LMICs with high levels of infectious disease exposure, breastfeeding is 
critical for early protection from diarrheal (and other) pathogens.  
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1.6.3. Micronutrient supplementation 
Among micronutrients, deficiencies of zinc and vitamin A have been implicated for 
association with increased diarrheal risk in the literature [3]. Among interventions for the 
prevention of diarrhea, zinc prophylactic supplementation has shown positive results in 
reducing the burden of diarrhea in LMICs [56-59]; however, clinical findings in 
numerous trials have not elucidated a mechanism(s) by which zinc may affect diarrheal 
risk, nor examined zinc associations with specific pathogens or class of pathogens. As 
reported in Chapter 2, we found no correlation between vitamin A (measured as retinol 
binding protein) and RV diarrhea in the PROVIDE Study; however infant serum zinc 
level was inversely associated with risk of RV diarrhea. 
 
1.7. The PROVIDE Study 
From 2010-2014, we conducted the “Performance of Rotavirus and Oral Polio Vaccines 
in Developing Countries” (PROVIDE) Study in a high-density urban slum in Dhaka, 
Bangladesh to better understand why oral vaccines (rotavirus and polio) perform sub-
optimally in LMICs. The study’s central hypothesis was that failure of oral vaccines is 
due to environmental enteric dysfunction (EED), a subclinical condition common in 
LMICs characterized by gut barrier dysfunction, malabsorption and permeability of the 
small intestine. The study design was 2x2 factorial with two interventional randomized 
controlled trials (RCT): a RV vaccine efficacy trial, reported here and in Chapter 2 [60], 
and a trial of the impact on mucosal immunity of an inactivated polio vaccine (IPV) boost 
on the standard oral polio vaccine (OPV) series. Results of the polio trial are reported 
elsewhere [61], and exploratory analysis of select biomarkers of EED and associations 
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with vaccine performance in the first year of life are published [6]. We enrolled 700 
infants in the first week of life and their mothers and followed them for two years. 
 
With the 2013 WHO recommendation for global roll-out of RV vaccines into all national 
immunization programs, PROVIDE was one of the last RCTs of RV vaccine efficacy in 
the pre-vaccination era. To date, Bangladesh has not added RV vaccine to the national 
program; however, GAVI has committed funding support for RV vaccine introduction, 
which is scheduled to begin in 2018. 
 
For the PROVIDE RV vaccine efficacy trial, infants were randomized 1:1 to receive RV1 
or no RV1 on a delayed dosing schedule of 10 and 17 weeks (vs 6 and 10 weeks on the 
standard WHO schedule). To better understand factors associated with RV vaccine 
efficacy, we collected extensive socio-economic, clinical and biologic data, including 
baseline household surveys, maternal surveys, comprehensive diarrhea surveillance, 
feeding practices, regular anthropometry, cognitive function assessments, blood, diarrheal 
and non-diarrheal stools, urine, saliva, and breast milk. Infants received all Bangladesh 
national Expanded Programme on Immunization (EPI) vaccines through the study clinic, 
which also provided free, high-quality primary care to both mothers and infants 
throughout study participation. Detailed study methods are published [62].  
 
As described in Chapter 2, in PROVIDE we found similar RV vaccine efficacy results 
compared to other trials in LMICs: 51% (95% CI, 33.8%–63.7%) against RV diarrhea 
(RVD) of any severity and 73.5% (95% CI, 45.8%–87.0%) against severe RVD in the 
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per-protocol analysis [60]. We modeled risk of RV diarrhea using multivariable logistic 
regression with 12 co-variates based on the literature and biologic plausibility, including 
RV vaccine, socio-demographic and household variables, sex, breastfeeding, RV IgA 
seroconversion and baseline infant health indicators (linear growth, retinol binding 
protein, vitamin D and serum zinc).  
 
In the final model, only lack of RV vaccine (OR 2.84, 95% CI 1.87–4.30) and serum zinc 
status (OR 0.77, 95% CI 0.66─0.91) correlated with risk of RV diarrhea in the first year 
of life: for every 10 µg/dL increase in serum zinc concentration (SZC), the odds of RV 
diarrhea decreased 23%. No interaction was detected between SZC and RV vaccine; the 
association between RV1 and RV diarrhea did not depend on zinc level (interaction term 
p > 0.33). For severe RV diarrhea, only vaccination correlated with risk of disease. 
 
Building on these results, Chapter 3 reports detailed analysis of the association between 
zinc deficiency in the PROVIDE cohort and risk of pathogen-specific diarrhea, as well as 
any viral diarrhea, using data from TAC analysis of PROVIDE diarrheal stool specimens. 
Compared to the current literature, this is the most complete evaluation of the association 
between zinc deficiency and specific pathogens to date. 
 
In PROVIDE, 16.5% of the per-protocol infant population (N=577) were serum zinc 
deficient at 18 weeks. These infants were 2.76 times more likely to have diarrhea in the 
first year compared to zinc replete infants (OR 2.76, 95% CI 1.08 – 7.04), and zinc 
deficient infants were nearly 4 times more likely to have viral diarrhea compared to non-
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zinc deficient infants (OR 3.94, 95% CI 1.55 – 10.03). Furthermore, in Kaplan Meier 
analysis, we found a strong correlation between zinc deficiency and time to first episode 
of viral diarrhea, with median survival time of 27 weeks among zinc deficient infants 
compared to 33 weeks in non-zinc deficient infants (p<0.0001). Infants with zinc 
deficiency were at 58% greater risk of viral diarrhea compared to non-deficient infants 
(HR 1.58, 95% CI 1.24 – 2.02).  
 
The strength of these findings, combined with the results of our RV vaccine efficacy trial 
(Chapter 2), led to an in-depth review of the zinc literature to better understand the clear 
association between zinc deficiency and diarrhea, and to generate hypotheses to 
interrogate the mechanism(s) of this association. 
 
1.8. Zinc as an essential trace metal 
Elemental zinc is essential to maintaining overall health and metabolism in humans as 
well as plants, invertebrates, vertebrates and microbes. Known as a Type II nutrient due 
to its ubiquitous roles, zinc catalyzes more than 300 metalloenzymes, anchors the 
structural integrity of the genome, and regulates gene expression. Zinc also plays crucial 
roles in cellular proliferation, differentiation and apoptosis, as well as in cell signaling, 
response to infection, and inflammatory processes [56, 63-65].  
 
1.9. Zinc bioavailability 
The richest sources of zinc are animal products: shell fish, red meats, and dairy products 
[66]. Zinc prolifically binds protein thereby facilitating zinc absorption in the intestines 
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during protein digestion. High-protein diets are uncommon in LMICs where plant-based 
diets are prevalent [67, 68]. In contrast to animal products, plant-based food sources are 
high in phytate, especially legumes and grains, which are the mainstays of the 
Bangladeshi diet (dal and rice). Phytate, the salt molecule of phytic acid found in plants, 
binds both dietary and endogenous zinc, reducing zinc’s bioavailability, blocking 
effective zinc absorption, and disrupting endogenous zinc homeostatic mechanisms [69]. 
While homeostatic regulation of zinc can cope with low zinc bioavailability in the 
absence of phytate, there does not seem to be an adaptation in adult humans to increase 
zinc absorption when faced with high phytate diets [70]. In this setting, reducing the ratio 
of phytate to zinc in dietary intake, development and distribution of zinc-fortified foods, 
fermentation to reduce phytate content in plant-based foods, or zinc supplementation are 
the available options for addressing this physiologic limitation [56, 71, 72].  
 
Interestingly, phytate inhibition of zinc absorption may be particular to adults. A 
compelling modeling exercise incorporating data from 8 studies showed a lack of effect 
of dietary phytate consumption on absorbed zinc among children aged 6 months – 13 
years [73], a finding supported by several studies in diverse geographic locations [74-76]. 
The authors hypothesized that phytate is hydrolyzed in the upper gastrointestinal tract of 
infants and children, who naturally have a higher stomach pH than adults, inducing 
enzymatic activity aimed at degrading phytate during early digestion. 
 
Relevant to this inquiry, the sole source of zinc nutrition for infants during EBF is from 
breast milk. Poor zinc nutrition in infants during EBF therefore is either a result of 
 20 
insufficient zinc in breast milk or poor absorption of zinc in the infant. One recent study 
in Thailand found correlations between zinc deficiency in infants and both maternal zinc 
status and zinc levels in breast milk [77]; however the same result was not found in 
several studies conducted 10 to 30+ years ago, as reviewed by Donangelo et al [78]. Zinc 
levels in breast milk have been shown to be conserved, even under maternal zinc stress, 
in a murine model, and one zinc supplementation trial of lactating human mothers 
showed no effect of supplementation on breast milk zinc levels [79, 80]. A 
comprehensive review by Brown et al concluded the most important determinant of 
breast milk zinc concentration is length of time post-partum (with breast milk zinc 
declining over time), as opposed to maternal zinc status [81]. 
 
Despite naturally declining zinc levels over the first 6 months post-partum, breast milk 
continues to be an important source of zinc after cessation of EBF, particularly where 
dietary zinc in complementary foods is suboptimal [81]. In the PROVIDE study, mean 
duration of EBF was 17 weeks, short of the WHO-recommended 24 weeks, after which 
the nutritional content in complementary foods becomes critical. In Bangladesh only 40-
45% of the recommended zinc intake for infants is met through breastfeeding plus typical 
complementary foods [82].  
 
1.10. Zinc homeostatic regulation 
Given the intrinsic importance of zinc in a multitude of cellular processes, zinc in the 
body is subject to tight homeostatic regulation. Zinc homeostasis is achieved through the 
balancing effects of zinc absorption and excretion, which maintain zinc equilibrium 
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across a broad range of dietary zinc intake levels. Both absorption and excretion take 
place primarily in the intestines, with some urinary excretion, and both are responsive to 
zinc status and changing physiologic needs [83, 84]. The highest rate of zinc absorption 
in the small intestine takes place in the jejunum, but the greatest volume in the duodenum 
[56]. Endogenous excretion of zinc into the intestinal lumen adjusts most rapidly to 
changes in zinc intake, with marked decreases in excretion under conditions of low 
dietary intake [85]. Zinc excretion occurs primarily via cellular release of zinc into the 
intestinal lumen followed by fecal excretion.  
 
In the setting of very low zinc intake, small zinc reserves in specific organs (liver, kidney, 
spleen and pancreas) or minute cellular reserves in organelle compartments may be 
tapped to maintain essential functions [56]. Bones hold approximately 30% of whole 
body zinc, and bone reserves seem to provide a zinc reservoir during very low intake, 
though the mechanism has not been characterized. It has been hypothesized that during 
low intake, bones forego their usual uptake of zinc from the serum to sustain other tissues 
(i.e. heart and muscles) [85]. 
 
Serum zinc level, which represents only approximately 1% of whole body zinc, is less 
responsive to changes in dietary zinc intake, except at very low levels of zinc availability, 
presumably to preserve circulating zinc for distribution to body tissues. Serum zinc 
concentration (SZC) does, however, respond quickly to initiation and cessation of zinc 
supplementation [86, 87]. Generally, clinical signs and symptoms of zinc deficiency are 
not detectable in advance of a precipitous drop in SZC. (Note: Although plasma versus 
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serum zinc concentrations (SZC) can differ slightly, likely due to differences in blood 
processing, they are both considered valid measurements of zinc levels in individuals 
[88].) Standard reference ranges for SZC, based on data from the National Health and 
Nutrition Examination Survey (USA), are published [56, 89]. Reference ranges for 
populations in LMICs are not available.  
 
At the cellular level, zinc homeostasis is mediated by methallothionein (MT) and zinc 
transporter proteins. Synthesis of MT, an intracellular zinc-binding protein discussed in 
detail below, is upregulated in the setting of increased intracellular zinc (i.e. through 
supplementation or dietary manipulation), as well as during acute phase responses, 
inflammation and oxidative stress. Zinc also signals MT for degradation. Zinc 
transporters have 2 distinct families: 14 Zrt- and Irt-like proteins (ZIP) import 
extracellular zinc and zinc held in the lumen of cellular organelles into the cytoplasm, 
and 9 known zinc transporter proteins (ZnT) move zinc from the cytoplasm into 
organelles or export it across the plasma membrane [90].  
 
1.11. Epidemiology and consequences of zinc deficiency 
Zinc deficiency (ZD) is highly prevalent in LMICs with 17.3% of the world’s population 
at risk [91]. Infants, children, and pregnant or lactating women have higher zinc 
requirements, putting them at increased risk of ZD and its sequelae. The global 
distribution of ZD resembles the geographic spread of highest risk for diarrheal morbidity 
and mortality; South Asia and Africa are at greatest risk with an estimated 30% and 25% 
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of the populations, respectively, consuming inadequate zinc. Among children under 5 
years, 14.5% of diarrheal deaths in Asia and Africa are attributable to ZD [92].  
 
Recent data from a cross-sectional study in Bangladesh showed an overall ZD prevalence 
of 44.6% in children age 6-59 months, edging up to 51.7% among children sampled from 
urban slums, like the PROVIDE population [68]. ZD prevalence in non-pregnant, non-
lactating women age 15-49 was 57.3% nationally and 66.4% in slums, with an 
astonishing 91% of women consuming inadequate dietary zinc to meet basic physiologic 
needs. Pervasive high-phytate, low animal-source diets were reported across the socio-
economic spectrum, but with pronounced imbalance among the lowest income 
participants. A separate study found a similar rate of ZD, 55%, in Bangladeshi women 
during early pregnancy (mean gestation, 3.6 months) [93].  
 
Consequences of zinc deficiency include increased susceptibility to infectious diseases 
such as diarrhea, stunting, impaired cognitive development, and in extreme cases, severe 
skin lesions [56, 89, 94]. Evidence from in vivo experiments of zinc restriction in adults 
demonstrated extensive dysfunction of the immune system in zinc deficiency, including 
dysregulated natural killer cell and TNF-α activity, thymic atrophy, aberrant lymphoid 
hematopoiesis, dysregulated NF-κB signaling, reduced CD4+ T cell function, and 
reduced immunoglobulin (Ig) responses [65, 95-99]. Zinc deficiency may disrupt the 
structural integrity of enzymes critical to V(D)J recombinase events, such as recombinase 
activating genes 1 and 2 (RAG1, RAG2), potentially limiting the repertoire of Ig’s and T 
cell receptors and leading to increased susceptibility to infections [100-102]. From 
 24 
murine models, immunologic consequences of gestational zinc deficiency have been 
suggested, with pups born from zinc-deprived dams exhibiting impaired humoral and 
cell-mediated immune responses for up to three generations [103, 104].  
 
1.11.1. Zinc deficiency and gut epithelial health and function 
Strong evidence, from both animal and human models, indicates a role of zinc deficiency 
in disrupting gut epithelial barrier function, which may have particular relevance to 
diarrheal risk [99]. Chai et al conducted a compelling study in a porcine model in which 
they demonstrated that piglets on a low zinc diet challenged with a porcine GI virus 
exhibited significant small intestine villous atrophy and reduced jejunal surface area 
compared to piglets on medium or high zinc diets with no post-challenge alteration in 
epithelial structure [105]. Furthermore, piglets on the high zinc diet experienced 
increased MT production and had higher and earlier antibody responses to viral challenge 
compared to low zinc piglets.  
 
The histologic changes described in low zinc piglets are consistent with environmental 
enteric dysfunction (EED), a pathologic spectrum of structural and functional 
abnormalities of the small intestine common in LMICs [106]. While the porcine study 
showed zinc deficiency contributing to altered gut epithelium, the direction of this 
relationship may not be straightforward. Evidence from a study among children in 
Malawi concluded that EED disrupts zinc homeostasis by inhibiting zinc absorption in 
the small intestine resulting in higher-than-expected fecal zinc excretion based on dietary 
intake and physiologic requirements [107]. Lindenmayer et al describe the complex 
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interplay between EED and zinc deficiency and develop a model of a vicious cycle in 
which both conditions contribute to intestinal permeability and malabsorption in the 
small intestine leading to immunologic dysregulation and increased susceptibility to 
infections, particularly by diarrheal pathogens [108]. Attributing cause and effect in the 
EED – zinc deficiency nexus, and its effect on risk of diarrhea in children, is complicated 
and requires detailed interrogation of basic mechanisms as well as translational studies in 
humans.  
 
1.12. Possible mechanisms for the association of zinc deficiency and viral diarrhea 
Findings from clinical research on zinc have contributed to characterizing the signs, 
symptoms and consequences of zinc deficiency; however; research specifically designed 
to test biologic pathways leading to increased risk of viral diarrhea is lacking. While 
many questions remain unanswered, two intriguing areas for future mechanistic 
investigation are highlighted here: dysregulated metallothionein transcription and 
application of the concept of nutritional immunity to zinc regulation as an innate defense 
against pathogens. Given the strong correlation found in PROVIDE between zinc 
deficiency and specifically viral diarrhea (Chapter 3), as well as the limited treatment 
options for viral diarrhea compared to other etiologies and the underperformance of 
rotavirus vaccines, emphasis is placed on the relationship of these mechanisms to viruses. 
 
1.12.1. Dysregulated metallothionein transcription in zinc deficiency 
Metallothionein (MT) is a low molecular weight, intracellular, cysteine-rich metal-
binding protein. A single MT protein can bind up to 7 zinc molecules, though MT has a 
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higher affinity for cadmium and copper. Increased free zinc levels in the cytoplasm 
induce metal regulatory transcription factor 1 (MTF-1) to initiate MT transcription [109-
111]. Strong evidence from porcine and murine models demonstrate MT transcription is 
initiated by increased intracellular zinc as an acute phase response (APR) to infection or 
injury (i.e. lung epithelial insult from mechanical ventilation), indicating a central role for 
MT in regulating zinc homeostasis and mediating the APR [111-113].  
 
Zinc deficiency has been shown to correlate with reduced MT expression [65, 113, 114]. 
One small study in humans (N=13) found, despite only a marginal decrease of 7% in 
plasma zinc concentration on a 7-day zinc-restricted diet, mean MT level fell by 68% in 
zinc-restricted human volunteers. By contrast, the same researchers found a 7-fold 
increase in mean MT concentration from 40 ± 6 µg/g protein to 273 ± 85 µg/g protein 
within 7 days on zinc supplementation (effect of supplementation on plasma zinc not 
reported) [115]. Two additional small studies in humans corroborate these results, 
particularly when measuring MT expression in monocytes [116, 117]. Due to its 
sensitivity to whole-body zinc levels, MT has been suggested for evaluation as a 
biomarker of zinc status [63].  
 
Based on these findings, it would be particularly interesting to evaluate whether MT 
expression differs in zinc deficient vs non-zinc deficient infants particularly during the 
acute phase of viral diarrheal illness (i.e. Day 1 of a diarrheal episode), which could 
illuminate critical pathways to preventing viral diarrheal disease. 
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1.12.2. Zinc and nutritional immunity 
The concept of “nutritional immunity” emerged out of the iron literature, but has since 
expanded to examine the role of other essential trace metals, including zinc, in regulating 
host response to pathogen presence as an innate defense against infection [118, 119]. 
Regarding zinc, substantial literature has described the role of nutritional immunity in the 
clearance of bacterial infections, in which intracellular zinc accumulation, either for zinc 
sequestration away from invading bacteria or zinc intoxication, particularly in 
phagocytes, leads to bacterial death [120-123]. The rationale for the intoxication defense 
involves the reliance of bacteria on zinc to support their own metabolic processes, similar 
to humans, making bacteria vulnerable to zinc toxicity. Few studies have investigated 
nutritional immunity as a defense strategy against viruses, which lack metabolic 
functions. In this case, zinc sequestration away from intracellular viral pathogens, as 
opposed to zinc accumulation for intoxication, may be the relevant nutritional immunity 
defense strategy.  
 
As described by Chaturvedi et al, zinc ions and zinc finger proteins (structural motifs 
with 4 cysteines facilitating zinc-binding [56]) are intrinsic to many viruses and play 
critical roles in viral transcription, replication, structural conformation and in counter-
defense to host immune responses [124]. On the host side, evidence from one small 
human study and one murine model showed increased MT expression specifically in 
response to viral infections (hepatitis C and coxsackievirus) [125, 126]. Given its strong 
binding affinity for zinc, increased intracellular MT would facilitate zinc sequestration by 
binding labile zinc. This has not been examined for viral diarrheal pathogens; however, 
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rotavirus provides a good model for consideration of how nutritional immunity may 
mediate the host:virus interface in virus-infected cells.  
 
Rotavirus is a triple-layered particle, which sheds its outmost layer of VP7 and VP4 upon 
cell entry, exposing the VP6 layer. Rotavirions rely on zinc ions to anchor the structure of 
the VP6 layer; however, the zinc recruitment strategy of rotavirus for this critical 
conformational element has not been characterized [127, 128]. Rotavirus also relies on 
zinc binding to interfere with host defense. Rotavirus non-structural protein 1 (NSP1) has 
been identified as an E3 ubiquitin ligase depending on an N-terminal zinc-binding 
domain to bind and target host interferon (IRF3) for proteasome degradation, thereby 
disrupting the host’s immune response to rotavirus infection [129].  
 
The importance of zinc in the “life cycle” of viruses suggests nutritional immunity, in this 
case the MT-mediated sequestration of zinc away from pathogens in the intracellular 
environment, may be important for clearance of viral infection. I hypothesize that 
reduced MT expression, as demonstrated in zinc deficiency, inhibits innate nutritional 
immunity against viral pathogens by reducing the cell’s ability to effectively sequester 
zinc leaving labile intracellular zinc available for recruitment by viruses. Furthermore, 
perhaps zinc supplementation in this context would promote adequate MT expression to 
restore nutritional immunity sequestration functions and provide protection from viral 
pathogens. These are areas for further investigation.  
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Notably, the ability of MT to effectively utilize zinc in nutritional immunity may be 
inhibited by heavy metal contamination. MT preferentially binds cadmium; however in 
the absence of sufficient MT expression, as in zinc deficiency, cells become vulnerable to 
cadmium toxicity, with consequences for zinc homeostasis [109, 130, 131]. This may be 
particularly problematic in populations subjected to high levels of environmental heavy 
metal contamination, such as in Bangladesh, and children may be at particularly high risk 
for heavy metal toxicity [132, 133]. The relevance of heavy metal contamination, 
particularly cadmium, to MT expression, zinc deficiency and risk of viral diarrhea 
remains unstudied.    
 
1.13. Zinc interventions: benefits and risks of supplementation  
for diarrhea prevention 
Finally, the potential for zinc supplementation interventions to positively impact diarrheal 
morbidity and mortality in children in LMICs must be addressed, with consideration of 
both infant and maternal supplementation strategies.    
 
1.13.1. Infant supplementation 
Several randomized clinical trials have found significant benefits of preventive zinc 
supplementation in children in ameliorating the burden of diarrhea [58, 134-136]; 
however zinc supplementation is not a panacea. Some trials have not found an effect of 
zinc supplementation on diarrheal prevalence or incidence, particularly among infants < 6 
months [87, 137, 138]. Furthermore, open debate remains regarding appropriate dosage, 
timing and delivery method for zinc supplementation, which may depend on the goal of 
 30 
supplementation: correcting the micronutrient deficiency vs preventing diarrhea 
associated with low zinc [139-141].  
 
On the vaccine front, Habib et al found no effect of zinc supplementation on oral polio 
vaccine immunogenicity, even though they demonstrated a significant difference in zinc 
levels between the intervention and control groups [142]. No similar study of the effect of 
zinc supplementation on RV vaccine immunogenicity has been published. The only clear 
effect of supplementation on vaccine response was in Bangladesh with a killed, subunit 
oral cholera vaccine [143], though results of this trial showed mixed effects: while the 
vibriocidal antibody response to vaccine was enhanced among zinc supplemented 
children, the cholera-toxin antibody response was suppressed. Finally, it is worth noting 
that many studies of zinc supplementation and vaccine response were conducted in HICs 
where zinc deficiency is less prevalent and therefore supplementation may be less 
effective in boosting vaccine responses.  
 
1.13.2. Maternal supplementation 
Evidence on the effects of maternal zinc supplementation on infant zinc status or diarrhea 
is scant. Regarding maternal supplementation and reduced diarrheal morbidity in infants, 
one double-blind, randomized controlled trial of maternal zinc supplementation (pre-natal 
through neonatal) in Peru found significant reductions in total days with diarrhea and 
incidence of diarrheal episodes lasting longer than 7 days among infants of supplemented 
mothers [118]. Two additional studies, in Bangladesh and Indonesia, found similar 
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benefits of maternal supplementation on infant diarrheal risk; this effect was only seen in 
low-birth weight infants [144, 145].  
 
Regarding maternal immunization, the limited data available showed no effect of zinc 
supplementation during pregnancy on infant responses to BCG or Hib vaccines; no 
results were reported for maternal immunization against diarrheal pathogens [146]. The 
potential for maternal zinc supplementation to positively impact infant diarrheal burden 
requires further investigation. 
 
For breastfed infants, important questions include whether maternal zinc supplementation 
improves zinc availability in breast milk and, if yes, whether this translates into improved 
zinc status in infants. A detailed review of the literature by Donangelo and King 
concluded the only consistently demonstrated effect of maternal zinc supplementation 
during lactation has been a slower rate of decline in breast milk zinc concentration 
compared to non-supplemented mothers [78]. No trials have tested whether zinc 
supplementation of mothers during breastfeeding correlates with improved zinc status in 
infants.  
 
Perhaps the strongest role for mothers in diarrhea prevention is through continued 
exclusive breastfeeding through the entire first six months of life. Public health programs 
should continue to promote EBF, particularly in populations tending to cease EBF prior 
to six months. The immunologic and nutritional benefits of EBF through six months 
cannot be overstated. With the introduction of complementary foods, community 
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education programs should emphasize locally-available and affordable options to ensure 
adequate zinc nutrition throughout early childhood. 
 
1.13.3. Risks of zinc supplementation 
Risks associated with zinc supplementation are rare, but include nausea, vomiting and 
diarrhea, and are usually seen only with zinc supplementation far exceeding the Tolerable 
Upper Intake Level for extended periods [56, 141, 147].  
 
1.14. Conclusions and future directions 
The mandate to effectively curb the excess burden of childhood diarrhea in LMICs 
persists as a top global public health priority in the 21st century. To reach the goal of 
reducing diarrhea-associated child mortality from 4.1 per 1000 live births (2013) to 1 per 
1000 live births by 2030, investments in new technology, clinical research and vaccine 
science must continue. However, complementary interventions are required as the 
research community continues to try to understand the challenges with vaccine 
underperformance (rotavirus), accelerating the pace of vaccine development for enteric 
diseases, and leveraging new technologies to increase our understanding of the complex 
biologic pathways contributing to risk of death or disability due to diarrhea in early life. 
 
Recent large-scale trials, including the PROVIDE Study, have clarified several important 
insights into the etiology of diarrhea in LMICs and possible interventions for 
ameliorating this burden. We now understand a single-pathogen model for diarrhea 
causation is too simplistic. The TAC platform illuminated pervasive carriage of 
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enteropathogens in both symptomatic children and children without diarrhea; the 
implications of which are actively under investigation. What is the optimal strategy for 
addressing the multiple co-pathogen burden, and how does this impact the efficacy of 
pathogen-specific vaccines or other diarrheal interventions? These are open questions in 
the field. 
 
Among currently available interventions for diarrhea prevention, we have vaccines for 
only one high-burden pathogen, rotavirus. While rotavirus vaccines have had a 
tremendous impact, they leave a gap in protection, particularly against diarrhea-
attributable morbidity. WASH interventions have not consistently demonstrated efficacy 
in preventing diarrhea, although the WASH Benefits Study may provide greater insight 
into optimizing WASH interventions for this goal. Promotion of exclusive breastfeeding 
(EBF) through 6 months and education on balanced complementary foods should 
continue to receive attention, particularly in populations tending to stop EBF prior to 6 
months and where traditional complementary foods offer sub-optimal nutrition.  
 
The PROVIDE Study also provided evidence that infant zinc level plays a significant role 
in risk of diarrhea, in particular from viruses, although this finding requires validation in 
larger cohorts, possibly GEMS and MAL-ED. There is also significant geographic 
overlap between risk of diarrhea and risk of zinc deficiency. However, many questions 
remain regarding associations and mechanistic pathways between zinc and particularly 
viral diarrhea that require synergistic, translational research to fully address. 
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The role of zinc in pathogen propagation and infection remains understudied. From the 
rotavirus model, we know zinc is intrinsic to the virus’ life cycle; the extent to which 
other high-burden diarrheal pathogens rely on zinc and specifically how viruses recruit 
and integrate zinc is uncharacterized. Does nutritional immunity with zinc extend to 
viruses, and what are the underlying mechanisms of this evolutionary arms race between 
host and pathogen? Does viral success in establishing infection relate to host 
metallothionein (MT) levels and the ability of the host to sequester zinc away from viral 
pathogens? Answers to these questions could elucidate mechanisms for focused 
development of effective interventions to prevent the establishment of diarrhea-
associated viral infections. 
 
Clinical investigations (i.e. observational and case-control studies) are required to 
determine whether MT transcription differs between zinc deficient and non-zinc deficient 
infants, particularly during the acute phase of infection. If yes, how does this relate to 
viral diarrheal risk? Can insufficient MT expression be corrected through zinc 
supplementation? Specific to LMICs with high rates of environmental enteric dysfunction 
(EED), untangling the cause-and-effect relationship between EED and zinc deficiency 
may contribute to our understanding of the determinants of infant zinc status and how this 
relates to viral diarrhea. Also relevant to many populations in LMICs, the role of heavy 
metal contamination in MT function and zinc homeostasis as it relates to risk of viral 
diarrhea requires further investigation with potential policy implications for affecting 
clean water and environmental standards. 
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Finally, carefully designed trials of zinc supplementation have the potential to determine 
whether zinc, as a complementary intervention in both infants and mothers, may fill the 
gap in protection against childhood diarrhea. In particular, zinc supplementation in 
infants < 6 months is understudied, and appropriate preventive dosages, delivery methods 
and timing of administration for optimal impact on viral diarrhea must be carefully 
considered. Furthermore, it remains unclear whether maternal zinc supplementation 
during lactation contributes to increased bioavailability of zinc in breast milk, and 
whether this could affect protective differences in infant zinc status between 
supplemented vs non-supplemented mothers. As future enteric vaccines become 
available, and for the current rotavirus vaccines, there are no data on the effect of infant 
or maternal zinc supplementation on infant vaccine outcomes, specifically in LMICs with 
highest risk of diarrhea. 
 
In conclusion, despite many unanswered questions, great progress has occurred and we 
now have additional tools at our disposal to attempt to reduce the continued burden of 
childhood diarrhea in the 21st century. This review delineates several key areas for future 
investigation to solidify our understanding of diarrhea and expand the available set of 
evidence-based interventions. The goals of elimination of childhood diarrheal mortality 
and reduced morbidity are within reach and must be achieved. 
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CHAPTER 2: DELAYED DOSING OF ORAL ROTAVIRUS VACCINE 
DEMONSTRATES DECREASED RISK OF ROTAVIRUS GASTROENTERITIS 
ASSOCIATED WITH SERUM ZINC: A RANDOMIZED CONTROLLED TRIAL 
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2.2. Abstract 
Background. Rotavirus is the world’s leading cause of childhood diarrheal death. Despite 
successes, oral rotavirus vaccines are less effective in developing countries. In an urban 
slum of Dhaka, we performed active diarrhea surveillance to evaluate monovalent G1P[8] 
rotavirus vaccine (RV1) efficacy and understand variables contributing to risk of 
rotavirus diarrhea (RVD).  
Methods. We performed a randomized controlled trial of monovalent oral rotavirus 
vaccine (RV1). Seven hundred healthy infants received RV1 or no RV1 (1:1) using 
delayed dosing (10 and 17 weeks) and were followed for 1 year. Intensive diarrhea 
surveillance was performed. The primary outcome was ≥1 episode of RVD. Nutritional, 
socioeconomic, and immunologic factors were assessed by logistic regression best-
subsets analysis for association with risk of RVD and interactions with vaccine arm. 
Results. Incidence of all RVD was 38.3 cases per 100 person-years. Per-protocol RV1 
efficacy was 73.5% (95% confidence interval [CI], 45.8%–87.0%) against severe RVD 
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and 51% (95% CI, 33.8%–63.7%) against all RVD. Serum zinc level (odds ratio [OR], 
0.77; P = .002) and lack of rotavirus immunoglobulin A (IgA) seroconversion (OR, 1.95; 
P = .018) were associated with risk of RVD, independent of vaccination status. Water 
treatment and exclusive breastfeeding were of borderline significance. Factors not 
associated with RVD included height for age at 10 weeks, vitamin D, retinol binding 
protein, maternal education, household income, and sex.  
Conclusions. In an urban slum with high incidence of RVD, the efficacy ofRV1 against 
severe RVD was higher than anticipated in the setting of delayed dosing. Lower serum 
zinc level and lack of IgA seroconversion were associated with increased risk of RVD 
independent of vaccination.  
Clinical Trials Registration. NCT01375647.  
Keywords. rotavirus diarrhea; zinc; oral vaccine; underperformance; developing 
countries. 
2.3. Introduction 
Rotavirus is the leading cause of child death from diarrhea. In 2008, prior to vaccine 
introduction, rotavirus diarrhea (RVD) caused approximately 453 000 deaths, most in 
South Asia and sub-Saharan Africa [1]. Three oral live attenuated rotavirus vaccines are 
now licensed and having tremendous impact: the 3-dose pentavalent human-bovine 
vaccine (RV5), the 2-dose monovalent G1P[8] vaccine (RV1), and the 3-dose human 
bovine G9P[11] vaccine (116E). In phase 3 trials, RV5 and RV1 have robust efficacy of 
>85% in high-income countries, as measured by protection from severe RVD or related 
hospitalization [2, 3]. In contrast, efficacy is markedly lower in developing countries: in 
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multiple clinical trials, oral rotavirus vaccine efficacy ranges from 18% to 61% in Africa 
and Asia [4–7].  
 
Although lower rotavirus vaccine efficacy in developing countries is well established, 
little is understood about the biologic basis of vaccine underperformance. Previous efforts 
have postulated mechanisms related to the vaccine itself, including dosing schedule and 
inoculum, and factors impacting the child’s ability to respond to vaccination [8]. The 
latter includes factors that prevent the vaccine from replicating in the intestine or blunt 
infant immune responses, such as breast milk and maternal antibody interference, 
enteropathy, and enteric coinfections [9–11]. Micronutrient deficiencies may also 
contribute; zinc specifically plays an extensive role in host defense and gut health, and 
deficiency has been associated with diarrheal morbidity and mortality [12, 13].  
 
To assess factors related to RV1 performance, we enrolled a 700-child birth cohort in an 
urban slum of Dhaka, Bangladesh, in the Performance of Rotavirus and Oral Polio 
Vaccines in Developing Countries (PROVIDE) study: a randomized controlled trial of 2-
dose RV1 vaccine using a delayed dosing schedule at 10 and 17 weeks of age (compared 
to the Expanded Programme on Immunization [EPI]–recommended schedule of 6 and 10 
weeks). With a primary outcome of any RVD post-vaccination to 1 year, we conducted 
biweekly home-based diarrhea surveillance for RVD. To inform public health 
interventions and vaccine development efforts, we determined RV1 efficacy in this 
population, assessed additional factors for associations with risk of RVD, and examined 
possible interactions with the vaccine. 
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2.4. Methods 
2.4.1. Study design and participants  
As part of the PROVIDE study, we performed a randomized, open-label, controlled trial 
of live oral G1P[8] rotavirus vaccine (RV1) in a birth cohort of 700 children from the 
Mirpur urban slum in Dhaka, Bangladesh. Infants meeting inclusion and exclusion 
criteria were enrolled in the first week of life. Detailed study methods including 
consenting and eligibility criteria, as well as results from PROVIDE on the association of 
environmental enteropathy, enteric infection, and small intestinal bacterial overgrowth on 
health outcomes, are published elsewhere [11, 14–16]. The study was approved by the 
ethical review boards of the International Centre for Diarrhoeal Disease Research, 
Bangladesh (icddr,b), the University of Vermont, and the University of Virginia. The 
study was registered at Clinicaltrials.gov (NCT01375647). 
 
2.4.2. Randomization and masking  
Children were randomized using permuted blocks with random block size selection (4 or 
8) and assigned to 1 of2 treatment groups: 50% (n = 350) to receive RV1 vaccine at 
weeks 10 and 17, and 50% no rotavirus vaccine. All clinical investigators and 
laboratories were masked to vaccine arm, but medical officers were not. 
 
2.4.3. Procedures  
The study was conducted from May 2011 through November 2013. Children were 
enrolled from birth to age 7 days in the home by trained field research assistants, 
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following comprehensive consenting procedures according to International Council on 
Harmonisation Good Clinical Practice guidelines. Mothers were administered a baseline 
survey at enrollment for demographics, household socioeconomic, water, and sanitation 
data.  
 
There were 10 clinic visits in the first year of life for anthropometry, phlebotomy, and 
vaccinations [14]. Children received the Bangladesh EPI vaccines, including trivalent 
oral polio vaccine at weeks 6, 10, and 14. All acute illnesses were evaluated by medical 
officers, and RV1 dosing was delayed in children presenting with fever at scheduled 
vaccination visits (n = 1). Breastfeeding was not withheld. Vaccine cold chain was 
reviewed before administration. Children with severe malnutrition (weight-forage z score 
< −3 SD) were referred for specialized care.  
 
Complete diarrhea surveillance was conducted throughout the first year of life [14]. Field 
research assistants visited households twice weekly to determine diarrheal episodes 
through a structured questionnaire. Diarrhea was defined as ≥3 abnormally loose stools in 
24 hours, per the mother, with distinct episodes separated by >72 hours diarrhea-free. 
Severe diarrhea was defined as Vesikari score ≥11 [17]. One diarrheal stool sample was 
collected during each episode. Mothers brought children into the clinic for further 
assessment and treatment of diarrheal illness. Diarrheal stool specimens were tested for 
rotavirus antigen by PosSpecT enzyme-linked immunosorbent assay (ELISA; Oxoid Ltd, 
Hampshire, United Kingdom).  
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Blood specimens for immunogenicity and micronutrients were collected at weeks 6 and 
18 into trace-metal free Vacutainer tubes and cryovials (Grenier Bio-One and 
ThermoScientific/Nunc, respectively). Plasma was evaluated for rotavirus-specific 
immunoglobulin A (IgA) antibodies as described [18]. In brief, a capture enzyme 
immunoassay (EIA) was performed using the rotavirus SA11 antigen; results were 
expressed as units per milliliter determined by positive control reference serum. 
Seropositive was defined as rotavirus IgA≥ 20 U/mL; seroconversion was defined as 
seropositivity at week 18 following a seronegative result pre-vaccination (week 6). 
Vitamin D and retinol binding protein were assessed using commercial ELISA kits 
(Immunodiagnostics Systems Ltd, Tyne, United Kingdom and R&D Systems, 
Minneapolis, Minnesota), and serum zinc was analyzed by flame atomic absorption 
spectrophotometer using WinLab32 software. 
 
2.4.4. Outcomes  
The primary outcome for intention-to-treat (ITT) efficacy analysis was 1 or more 
episodes of RVD from birth to 1year. RVD was defined as diarrhea positive for rotavirus 
antigen by ELISA. Secondary outcomes were severe RVD, all-cause diarrhea (diarrhea of 
any etiology) and all-cause severe diarrhea in the first year of life, and any and severe 
RVD post-vaccination, from 18 to 52 weeks of age. Missed diarrheal stool specimens 
were assumed negative for rotavirus. Rates of missingness are reported [14]. 
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2.4.5. Statistical analysis  
The trial was designed with at least 90% power to detect 50% vaccine efficacy at α = .05, 
assuming rotavirus infection in 26% of non-vaccinated children by 1 year. Primary 
analysis was by ITT: all randomized subjects were included regardless of whether they 
adhered to the protocol vaccine regimen or terminated study participation prior to 1 year. 
Secondary per-protocol (PP) analyses were performed including all children who had 365 
days of follow-up and, if assigned to the vaccine arm, received both doses of rotavirus 
vaccine within the protocol-specified window.  
 
Vaccine efficacy was calculated using the standard formula: 
(ARUNVAX – ARVAX) / (ARUNVAX ×100), with ARVAX the attack rate in vaccinated and 
ARUNVAX the attack rate in unvaccinated individuals. For dichotomous clinical outcomes, 
proportions of children with diarrhea along with Wilson 95% confidence intervals (CIs) 
and absolute risk differences in vaccinated and unvaccinated groups were calculated [19, 
20]. 
 
Considering the study size and limitation on outcome events, a limited pool of 12 
explanatory variables was selected a priori for analysis by best-subsets multivariable 
logistic regression to determine a model for risk of RVD based on the literature, biologic 
plausibility, and data availability. The best subset of p variables was chosen for the 
minimum Mallows’ Cp statistic for which Cp < p [21]. From this main effects model, all 
2-way interactions were tested by change in deviance from the reduced model (likelihood 
ratio test). Model diagnostics included inspection of residuals, influential cases, and 
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linearity in the logit for continuous variables. The Hosmer-Lemeshow goodness of fit test 
was performed. Raw P values (Wald test) for regression coefficients were adjusted for 
multiplicity post hoc using a stepdown Holm procedure [22]. The final model for RVD 
was then applied to the clinical outcome of severe RVD. Analyses were performed using 
SAS software version 9.3 (SAS Institute, Cary, North Carolina). 
 
2.5. Results 
2.5.1. Study population  
After a community-wide survey of Mirpur, Dhaka, Bangladesh, 700 mother-child pairs 
were consented and enrolled within 7 days of birth (median age, 5 days [range, 1–7 
days]) (Figure 2.1.). Children were randomized to receive the 2-dose RV1 vaccine at 10 
and 17 weeks of age or not. Population characteristics by randomization arm are shown 
in Table 2.1.. There were no differences in characteristics between arms, except in 
rotavirus IgA seroconversion (26.8% seroconverted among vaccinated vs 17.2% in 
unvaccinated children; P = .005) and rotavirus IgA geometric mean titer (GMT) at week 
18 (12.2 U/mL in vaccinated vs 4.3 U/mL in unvaccinated children; P = 2.4 × 10−8). 
There were 92 dropouts, 12% (n = 43) in the RV1 arm and 14% (n = 49) in the control 
arm (P = .53). 
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Figure 2.1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram.  
Abbreviation: RV1, monovalent G1P[8] rotavirus vaccine. 
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Table 2.1. Characteristics by randomization arm 
 Randomization Arm 
 RV1 arm (n=350) No RV1 arm (n=350) 
Child features 
   Sex, male  182 (52.0) 186 (53.1) 
   Median age at enrollment, d 5  (1 – 7) 5  (1 – 7) 
   Median weight at enrollment, kg 2.7 (1.7 – 4.1) 2.8 (1.9 – 4.0) 
   Median length at enrollment, cm 48.5 (43.1 – 55.4) 48.8 (44.5 – 54.6) 
   Median height-for-age z score at 10 wka -0.98 (-3.54 – 2.67) -0.89 (-4.36 – 1.69) 
   Median weight-for-age z score at 10 wk a -0.91 (-4.53 – 1.83) -0.86 (-3.61 – 1.40) 
   Exclusive breastfeeding at 18 wkb 154 (50.0) 161 (53.5) 
   Home birth 100 (28.6) 81 (23.1) 
Maternal features 
   Median age at enrollment, y 24  (18 – 40) 24  (18 – 41) 
   Vaginal delivery 277 (79.1) 263 (75.1) 
   Median height, cmc 150  (137– 187) 150  (134 – 167) 
   Median post-partum weight, kgc 48.0  (30.2 – 80.0) 47.0  (30.0 – 77.0) 
   Other children ≤5 y old in home 92 (26.3) 96 (27.4) 
   Mother education class 9+ 54 (15.4) 55 (15.7) 
Household and Socioeconomic features   
   Median total monthly income, 1000 taka 10 (3 – 77) 10 (3 – 70)  
   Piped municipal water 339 (96.9) 339 (96.9) 
   Toilet or septic tank 195 (55.7) 172 (49.1) 
   One-room home 251 (71.7) 256 (73.1) 
   Median No. of household members  5 (1 – 16)  4  (2 – 18) 
   Any water treatment 209 (59.7) 211 (60.3) 
Immunogenicity   
   RV IgA seroconversion d 80 (26.8)* 50 (17.2)* 
   RV IgA geometric mean titer, U/mLe 12.2** 4.3** 
Serum Micronutrients at 18 weeks   
   Zinc, µg/dL f 75 (44 – 173) 77 (55 – 150) 
   Vitamin D, nmol/L g 58.8 (15.1 – 146.1) 58.1 (13.2 – 139.9) 
   Vitamin A, µg/ml g 26.1 (6.0 – 99.8) 25.8 (4.8 – 99.9) 
  Data are presented as No. (%) or median (range). 
  Abbreviations: IgA=immunoglobulin A; RV=rotavirus; RV1=monovalent G1P rotavirus vaccine. 
  a N=318 RV1 arm, N=326 No RV1 arm 
  b N=308 RV1 arm, N=301 No RV1 arm 
  c N=330 RV1 arm, N=339 No RV1 arm 
  d N=299 RV1 arm, N=291 No RV1 arm 
  e N=289 RV1 arm, N=269 No RV1 arm 
  f N=300 RV1 arm, N=301 No RV1 arm 
  g N=305 RV1 arm, N=294 No RV1 arm 
  *P = 0.005, Chi-square test. ** P = 2.4 x 10-8 
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2.5.2. Rotavirus diarrhea incidence and vaccine efficacy  
Under intense surveillance, incidence of RVD in unvaccinated children in the densely 
populated urban slum was 38.3 cases per 100 person-years, higher than previously 
reported in developing countries [4, 5, 7] (Table 2.2.). In the primary analysis, vaccinated 
children vs unvaccinated had significantly less RVD (19.1% vs 32.6%) and severe RVD 
(4% vs 11.1%) in the first year of life (Table 2.3.). Overall, by ITT analysis, vaccine 
efficacy was 41.2% (95% CI, 23.6%–54.8%) against all RVD and 64.1% (95% CI, 
35.1%–80.1%) against severe RVD. The number of children needed to treat to prevent 1 
case of RVD, derived as the reciprocal of the absolute risk difference, was 8 (95% CI, 6–
15). There were 3 cases of RVD and 2 cases of severe RVD between week 6, first dose of 
the EPI-recommended RV1 dosing regimen, and week 10 when the first dose ofRV1 was 
given in PROVIDE. Efficacy estimates against all-cause diarrhea were 1.3% (95% CI, 
−4.8% to 7.1%) for any diarrhea and 12.7% (95% CI, −7.5% to 29.1%) for severe 
diarrhea. 
Table 2.2. Incidence of rotavirus diarrhea in “Performance of Rotavirus and Oral Polio Vaccines in 
Developing Countries” Study compared with other cohorts 
 Rotavirus Diarrhea Severe Rotavirus Diarrhea 
Cases (N) Person Years Incidence
 a  Cases (N) Person Years Incidence
 a 
PROVIDE (urban, 
unvaccinated) 121 315.9 38.3 41 315.9 13 
Rural Bangladesh and 
Vietnam [4] 109 1143.4 9.5 71 1156.9 6.1 
Sub-Saharan Africa [5] 294 2556.3 11.5 129 2585.9 5.0 
South Africa and 
Malawi [7] NA NA NA 70 NA 8.0 
Abbreviations: NA, not available; PROVIDE, Performance of Rotavirus and Oral Polio Vaccines in 
Developing Countries study. a Incidence per 100 person-years. 
 
PP analysis of efficacy post-vaccination (18–52 weeks) was performed. PP efficacy 
against all RVD was 51%(95%CI, 33.8%–63.7%) and 73.5% (95% CI, 45.8%–87.0%) 
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against severe RVD (Table 2.3.), while efficacy against any and severe all-cause diarrhea 
was −3.1% (95% CI, −9.2% to 2.7%) and 22.1% (95% CI, −3.0% to 41.1%), 
respectively. 
Table 2.3. Rotavirus diarrhea incidence and vaccine efficacy, intention-to-treat and per-protocol 
analyses 
 
Abbreviations: CI, confidence interval; ITT, intention-to-treat; RR, relative risk; RV1, monovalent G1P[8] 
rotavirus vaccine; RVD, rotavirus diarrhea. 
 
 
2.5.3. Best subset of factors associated with rotavirus diarrhea and vaccine 
interactions  
There were 555 children with complete data for all 12 explanatory variables in the best-
subsets modeling of risk of RVD post-vaccination to 1 year. The explanatory variable 
pool consisted of rotavirus vaccine arm, household income, sex, delivery status (cesarean 
vs vaginal), mother’s education (below class 9 vs class 9 and above), household water 
treatment (yes/no), exclusive breastfeeding at 18 weeks (yes/no), rotavirus IgA 
seroconversion (IgA < 20 U/mL at 6 weeks and ≥20 U/mL at 18 weeks), 
height-for-age z score (HAZ) at 10 weeks, and retinol binding protein, vitamin D, and 
serum zinc at 18 weeks.  
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In the multivariable best-subsets logistic regression analysis, the most parsimonious main 
effects model (minimum Cp < p) was the 5-variable model including vaccination arm, 
serum zinc, IgA seroconversion, exclusive breastfeeding, and water treatment. No 2-way 
interactions were statistically significant; no variable impacted the effect of rotavirus 
vaccine on risk of RVD (interactions with vaccine arm P > .33). The Hosmer-Lemeshow 
goodness-of-fit test for the main effects model was performed (P = .67). Based on model 
diagnostics, removing the 5 cases most poorly fit by the model (change in deviance P < 
.005 with largest leverage) strengthened the odds ratio (OR) point estimates by 
approximately 10% for vaccination arm, seroconversion, and serum zinc. There was no 
expectation these cases were different from the study population, so results include all 
cases.  
 
Variables most strongly associated with risk of RVD were not receiving RV1 (OR, 2.84 
[95% CI, 1.87–4.30]), serum zinc level (OR, 0.77 [95% CI, .66–.91]), and lack of IgA 
seroconversion (OR, 1.95 [95% CI, 1.12–3.39]). Absence of water treatment and not 
exclusively breastfeeding were also associated with increased risk of RVD (ORs of 1.50 
and 1.46, respectively; Table 2.4.). The effects of RV1 and serum zinc retained statistical 
significance after adjusting for multiple testing. 
 
The final model selected for the RVD outcome was applied to severe RVD. Only lack of 
vaccine was significantly associated with increased risk of severe RVD (OR, 3.81 [95% 
CI, 1.78– 8.82]; P = .0008; Table 2.4.). The coefficients and effect size estimates for all 
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variables were comparable to the all-severity RVD model, although cases of severe RVD 
(incidence rate, 7.4%) were insufficient to meet statistical significance. 
 
Table 2.4. Multivariable logistic regression main effects model for risk of rotavirus diarrhea and 
severe rotavirus diarrhea 
Variable Coefficient (SE) 
Odds Ratio  
(95% CI) 
Main 
effect raw 
P value 
Main 
effect  
adj. P 
value 
Rotavirus Diarrhea post week 18 in year 1 
No RV1 arm (control) 1.04 (0.68) 2.84 (1.87 – 4.30) 9.6 × 10–7 1.4 × 10–5 
Zinc, 18 weeks (x 10ug/dL) -0.26 (0.08) 0.77 (0.66 – 0.91) 0.002 0.024 
Lack of RV IgA seroconversion 0.67 (0.28) 1.95 (1.12 – 3.39) 0.018 0.228 
Absence of water treatment 0.40 (0.40) 1.50 (0.99 – 2.24) 0.051 0.612 
Stopped excl. breast feeding by week 18 0.38 (0.20) 1.46 (0.97 – 2.18) 0.066 0.726 
Severe Rotavirus Diarrhea post week 18 in year 1 
No RV1 arm (control) 1.37 (0.39) 3.93 (1.83 – 8.47) 0.0005 0.008 
Zinc, 18 weeks (x 10ug/dL) -0.12 (0.13) 0.88 (0.69 – 1.13) 0.325 1.000 
Lack of RV IgA seroconversion 0.59 (0.50) 1.81 (0.68 – 4.81) 0.233 1.000 
Absence of water treatment 0.54 (0.33) 1.72 (0.92 – 3.30) 0.099 1.000 
Stopped excl. breast feeding by week 18 0.47 (0.33) 1.59 (0.83 – 3.07) 0.163 1.000 
Raw P values from Wald test and adjusted using Holm stepdown procedure.  
Abbreviations: CI, confidence interval; IgA, immunoglobulin A; RV, rotavirus; RV1, monovalent G1P[8] 
rotavirus vaccine; SE, standard error. 
 
2.6. Discussion 
Using a clinical primary endpoint of RVD, we performed a controlled efficacy trial of 
oral rotavirus vaccine given at 10 and 17 weeks after birth. The study was performed in a 
highly rotavirus-endemic, densely populated, urban setting in Bangladesh. PP analysis 
allowed comparison of our vaccine efficacy estimates with large phase 3 trials ofRV1 [4, 
7]. Following a delayed dosing regimen, the efficacy of RV1 vaccine to prevent severe 
RVD was 73.5% (95% CI, 45.8%–87.0%), higher than previously reported in developing 
countries, including 45.7% efficacy against severe RVD in Bangladesh [4]. Vaccine 
efficacy against RVD of any severity was 51% (95% CI, 33.8%–63.7%). Although past 
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studies have suggested that rotavirus vaccine may protect against diarrhea from all 
etiologies [2, 4], we saw no impact of rotavirus vaccination on all-cause diarrhea.  
 
We postulate our improved efficacy was due to several factors in our study design. 
Intense community-based diarrhea surveillance captured higher than expected incidence 
of RVD (including mild cases not requiring medical attention). This high incidence 
exposes the large burden of rotavirus disease and contributes toward higher vaccine 
efficacy. Additionally, although not directly tested, our delayed dosing schedule at 10 and 
17 weeks may have minimized maternal antibody interference with RV1 vaccine. 
Although previous efficacy trials [4, 7] and immunogenicity studies [23, 24] have tested 
2–3 doses of rotavirus vaccine administered between 6 and 16 weeks, this work is the 
only efficacy trial with delayed dosing (10 and 17 weeks). An additional trial, using a 
clinical endpoint to compare early vs late dosing schedules, would be necessary to 
confirm superiority of delayed dosing. With only 5 cases of RVD between the currently 
EPI-recommended start of vaccination (week 6) and week 10 (used here), the added risk 
of delaying dosing appears minimal.  
 
To further understand risk of RVD, we used multivariable best-subsets analysis to 
evaluate factors for association with risk of RVD, including nutritional, socioeconomic, 
hygiene, and immunologic variables. Beyond vaccination, only serum zinc and IgA 
seroconversion were strongly associated with protection from RVD, and both were 
independent of vaccination status. This suggests that, regardless of vaccine performance, 
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improvement in these variables would decrease risk and overall burden of RVD. In the 
final model, only vaccination and serum zinc level retained significance.  
 
The observation that serum zinc is associated with decreased risk of RVD (OR, 0.77; P = 
.002) recalls the importance of zinc in intestinal epithelial repair and immunologic 
response mechanisms critical for mucosal protection [12, 25]. Previous studies have 
demonstrated a clear benefit of both supplemental and therapeutic zinc in protection from 
diarrheal disease in infants [13, 26]; however, there have been mixed results regarding 
the benefits of zinc specifically in RVD [27, 28]. We did not find an association between 
zinc and all-cause diarrhea.  
 
Relevant to interpretation of our zinc findings, there has been controversy about the value 
of serum zinc level as a biomarker of individual zinc status; however, the recently 
published review of zinc under the National Institutes of Health’s Biomarkers of 
Nutrition for Development (BOND) program [29] supports the use of serum zinc for this 
purpose as it relates to clinical signs of zinc deficiency, is responsive to zinc 
supplementation interventions, and can predict functional responses to supplementation, 
particularly in populations where functional bioindicators (i.e., low HAZ scores) suggest 
risk of zinc deficiency. With a stunting prevalence exceeding 20% by 1 year of age, the 
PROVIDE cohort meets BOND’s recommended threshold for populations in which 
serum zinc may be a particularly strong biomarker of zinc status, lending confidence to 
the interpretation of our findings.  
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As in the PROVIDE study, a disconnect has been noted in several trials in developing 
countries between development of rotavirus-specific IgA and vaccine efficacy [9]; 
however, our findings regarding immunologic responses raise concern. Less than one-
third of PROVIDE children seroconverted following vaccination, and IgA GMTs were 
markedly lower in PROVIDE, even compared to another cohort in Bangladesh that found 
GMTs of47 U/mL among vaccinated children [30]. Importantly, immunogenicity in 
PROVIDE was measured 1 week after the second dose of vaccine (week 18), whereas 
other studies examined IgA 1–2 months after the second dose. Another possible 
contributing factor may be the difference in antigenic lysate used in the capture EIA 
assay in PROVIDE (rotavirus SA11 antigen) vs other studies.  
 
Although not reaching statistical significance at the P ≤ .05 level, other potential risk 
factors for RVD warrant further investigation in larger studies. Lack of exclusive 
breastfeeding and absence of water treatment in particular, together with zinc 
supplementation and vaccination, might be envisioned as the core of a focused diarrhea-
prevention public health plan offering both vaccination and improved baseline health to 
reduce the burden of RVD.  
 
Our work has several limitations. Although we performed intense diarrhea surveillance, 
results may underreport the incidence of short-duration diarrheal episodes. We assumed 
these episodes were negative for rotavirus, which may downwardly bias our efficacy 
estimates. The Hawthorne effect, in which enrolled children receive higher-standard 
primary care, may be present and upwardly bias efficacy estimates. Our sample size and 
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number of outcome events limited the explanatory variables in our best-subsets analysis; 
our results need confirmation in larger studies. Additionally, we measured post-
vaccination immunogenicity earlier than comparable trials. Although our results may 
reflect poor primary response or poor boosting after the second dose of RV1, our data 
could have underestimated immunogenicity based on this earlier time point.  
 
Additional data are necessary to fully understand the limitations of oral vaccine efficacy 
in developing countries and delineate the optimal response. Previously we described the 
association of concurrent enteroviruses, as well as environmental enteropathy (measured 
by fecal reg1B, neopterin, serum soluble CD14, and enteric infection), on RV1 failure 
[11, 16]. Future work will focus on the impact of maternal antibodies and blood group 
antigens, the role of enteric co-pathogens, the effect of zinc supplementation and whether 
zinc has a pathogen-specific effect in protection from diarrheal disease, and the role of 
asymptomatic infection in IgA seroconversion and rotavirus vaccine performance. 
Research toward the identification of more predictive immune correlates of protection for 
rotavirus is also under way (B. D. Kirkpatrick, personal communication). With high 
efficacy against severe RVD, our work demonstrates the importance of oral rotavirus 
vaccines in highly endemic settings and suggests that support of baseline health and 
sanitation are still critical components of a public health approach, including vaccination, 
to prevent morbidity and mortality due to rotavirus diarrhea. 
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CHAPTER 3: ZINC DEFICIENT INFANTS AT HIGH RISK OF VIRAL 
DIARRHEA IN A BANGLADESHI BIRTH COHORT 
 
3.1. Introduction 
Diarrhea remains the second leading cause of child mortally globally. A significant 
proportion of infectious diarrhea in infants is due to viral pathogens, which now can be 
detected more readily with the use of quantitative multiplex PCR technologies [1]. 
Among all diarrheal pathogens, rotavirus (RV) accounts for the highest attributable 
incidence of diarrheal disease and mortality in the first year of life [2]. Prevention of RV 
and other viral diarrhea may be best addressed by vaccination. However, oral RV 
vaccines consistently show sub-optimal efficacy of 18-61% in low and middle-income 
countries (LMICs) with further evidence of waning effectiveness in year 2 [3-6], and no 
vaccines are available for other leading viral diarrheal pathogens, specifically norovirus 
and adenovirus 40/41. Furthermore, unlike bacterial infections for which antibiotics are a 
treatment option, treatment of viral diarrhea is limited to oral rehydration solution and 
zinc. A gap in protection against viral diarrhea exists in LMICs, and complimentary 
strategies for diarrhea prevention are critical. 
 
Zinc deficiency (ZD) is prevalent in LMICs with a high burden of RV and other diarrhea, 
particularly South Asia and Sub-Saharan Africa [7, 8]. ZD has been linked to 
dysregulation of biologic processes that may lead to increased risk of diarrhea, including: 
poor gut epithelial repair and barrier function, immune and inflammatory dysfunction, 
and aberrant microbiota composition [9-11]. Zinc deficiency in LMICs is complex. In 
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these settings, children often are infected with multiple co-pathogens and experience high 
rates of gut and systemic inflammation [12, 13], complicating interpretations of zinc 
deficiency with zinc biomarkers responsive to acute-phase inflammatory processes [14]. 
Zinc deficiency in infants also may be tightly linked to maternal zinc nutrition, obscuring 
the optimal target population for possible zinc interventions [15]. 
 
A significant body of evidence from LMICs demonstrates beneficial effects of zinc 
interventions in children to treat diarrhea; however, less conclusive evidence from 
randomized controlled trials is available for zinc in diarrhea prevention. One meta-
analysis estimated preventive zinc supplementation of ≥ 3 months was associated with 
14% reduction in diarrheal incidence (RR 0.86, 95% CI: 0.79–0.93) [16], while other 
trials have not demonstrated an effect, particularly among infants < 6 months [17, 18]. 
Most trials of zinc supplementation have not distinguished diarrheal risks or responses 
between children with vs without zinc deficiency at baseline. 
 
In our past work evaluating rotavirus vaccines in Dhaka, Bangladesh (“Performance of 
Rotavirus and Oral Polio Vaccines in Developing Countries” (PROVIDE) Study) [19, 
20], we demonstrated that week 18 serum zinc concentration correlated with risk of 
subsequent RV diarrhea from week 18–52 of life (OR 0.77, 95% CI (0.66-0.91), 
independent of RV vaccination. This surprising correlation suggests focused 
consideration of of zinc supplementation in populations at high risk of rotavirus diarrhea 
to address the gap in vaccine protection. 
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However, this observation also illustrates gaps in knowledge regarding the relationship 
between infant zinc status and infectious diarrhea, which require better understanding to 
guide the use of preventive zinc supplementation. Of interest, previous studies have not 
assessed whether zinc is particularly effective against specific diarrheal pathogens, and 
whether additional risk factors impact pathogen-specific diarrheal risk related to zinc 
deficiency. 
 
With the ultimate goal of optimizing preventive strategies against childhood diarrhea, 
herein we seek to more comprehensively understand the important associations of zinc 
deficiency and infectious diarrhea, and to evaluate co-factors including inflammatory 
markers, breastfeeding practices, breast milk composition and demographics for possible 
effects on the zinc-diarrhea relationship. Given the high burden of RV and other viral 
pathogens in the first year of life, a unique relationship between higher zinc levels and 
protection against viral diarrhea would support consideration of zinc interventions to 
address the gap in protection against childhood diarrhea. 
 
3.2. Methods 
3.2.1. Study design and population 
We conducted a formal randomized controlled trial of oral rotavirus vaccine efficacy 
under the PROVIDE Study from May 2011 – November 2013 in a birth cohort of 700 
infants in an urban, high-density, low-income section of Dhaka, Bangladesh, where 
rotavirus vaccine is not routinely administered. Eligible infant-mother pairs were enrolled 
in the first week post-partum following consent of the mother, and infants were 
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randomized 1:1 to receive oral Rotarix™ vaccine (RV1) or no RV1 at weeks 10 and 17. 
Infants were followed for one year in the RV1 trial. Detailed eligibility criteria and 
consenting and randomizations procedures are described elsewhere [19, 20]. The study 
was conducted per Good Clinical Practice guidelines, and the study was approved by 
ethical review boards at the International Centre for Diarrhoeal Disease Research, 
Bangladesh (icddr,b) and the Universities of Vermont and Virginia. Clinicaltrials.gov 
registration is NCT01375647. 
 
3.2.2. Clinical procedures 
Mothers’ study participation included completing detailed questionnaires on household 
demographics, water and sanitation, socioeconomic status, and personal reproductive 
history, as well as breast milk specimen collection within 6 weeks of enrollment. Infants 
were scheduled for 10 study visits in one year for receipt of routine childhood 
immunizations (per Bangladesh’s national program) and RV1 vaccine, anthropometry 
and blood draws. Interim clinic visits for acute illness and diarrheal assessments occurred 
as needed. All acute care treatments prescribed through the study clinic were recorded. 
 
Active, community-based diarrhea surveillance consisted of twice weekly home visits by 
trained Field Research Assistants to capture infants’ history of diarrhea, fever, and 
vomiting, home use of antibiotics and oral rehydration solution, and breastfeeding 
practices. Infants with diarrhea were referred to the study clinic for assessment. Mothers 
or study field assistants collected one diarrheal specimen per episode, defined as ≥ 3 
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loose stools in 24 hours per the mother with three diarrhea-free days distinguishing 
episodes. 
 
3.2.3. Laboratory procedures 
Each diarrheal specimen was analyzed by quantitative real-time PCR, TaqMan Array 
Card (TAC), for 35 enteropathogen targets. Detailed methods for development, validation 
and optimization of the TAC assay have been published [21-23]. Briefly, QIAamp Fast 
DNA Stool mini kits were used for nucleic acid extractions, which were then run in 
individual pathogen-specific probe-based assays compiled on a single card, including two 
external controls. The assay read-out was a Quantification Cycle (Cq) value, representing 
the amplification cycle number at which flouresced pathogen-specific nucleic acid was 
detectable above background, with a positive range of 0 < Cq < 35. 
 
For this analysis, the top seven pathogens identified in previous studies for diarrhea 
attributable incidence in the first year of life in LMICs were selected from the TAC 
panel: rotavirus, adenovirus 40/41, norovirus, Campylobacter jejuni, Shigella 
spp/enteroinvasive E. coli (EIEC), heat-stable enterotoxigenic E. coli (ST-ETEC), and 
Cryptosporidium spp [1, 24, 25]. Non-polio enterovirus (NPEV) was also included based 
on previously reported high prevalence of NPEV infection in the PROVIDE cohort [26]. 
Published diarrhea-associated TAC Cq cut-offs for each pathogen were applied for 
assigning pathogen etiology in diarrheal specimens; extensive methods for determining 
diarrhea-associated TAC Cq’s are described elsewhere [1, 21, 23, 25, 27]. No diarrhea-
associated Cq threshold has been defined for NPEV, Cq < 35 was used. 
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Blood specimens for serum zinc concentration (SZC) and acute phase inflammatory 
markers interleukin-6 (IL-6) and C-reactive protein (CRP) were collected at week 18 in 
trace metal-free Vacutainer tubes and cryovials (Grenier Bio-One and 
ThermoScientific/Nunc). Specimens were centrifuged and 25-30 μL of serum aliquoted 
for SZC measurement and stored at < -70ᵒ C for 4 to 28 months prior to analysis by flame 
atomic absorption spectrophotometer usingWinLab32 software. Zinc deficiency was 
defined as SZC < 65μg/dL based on suggested SZC cut-offs from the BOND Zinc Expert 
Panel Review and sensitivity analysis in the PROVIDE dataset [28]. Serum IL-6 was 
analyzed by BioRad’s 17-plex Bio-Plex Cytokine Assay kit (Cat # M50-00031YV). 
Serum CRP was assessed by ALPCO ELISA kit assay per the manufacturer’s instructions 
(Cat # K-9710s). 
 
Detailed methods for breast milk specimen collection, processing and analysis are 
published [29]. Briefly, within six weeks of enrollment specimens were expressed 
directly into 5mL falcon tubes at the mother’s convenience after instruction on manual 
expressing by field staff. Samples were collected from mothers and transported to the 
icddr,b laboratory at 4ᵒ C where dried milk spot cards were prepared with 50μL breast 
milk and anti-oxidant pre-treatment prior to shipping to OmegaQuant Analytics, Sioux 
Falls, SD. The cards were analyzed by gas chromatography for 26 breast milk fatty acids, 
including linoleic acid (LA) and dihomo-γ-linoleic acid (DGLA). The ratio of LA:DGLA 
in breast milk was included as a potential marker of maternal zinc status [30, 31]. 
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3.2.4. Statistical analysis 
Frequencies for select enteropathogens in diarrheal specimens were determined as total 
number of pathogen-specific positive TAC results (0 < Cq < diarrhea-associated Cq cut-
off) over total number of evaluated stools (N=1,367). Incidence per infant was calculated 
as ≥ 1 pathogen-specific episode of diarrhea from weeks 18-52, using the same diarrhea-
associated Cq cut offs. Diarrheal stools or episodes with more than one select pathogen 
present at diarrhea-associated levels were counted for each pathogen(s). Infants were 
excluded from pathogen-specific analysis if they had missing stools plus only negative 
TAC results for a pathogen in evaluated stools. Infants with a positive TAC result in any 
evaluated stool were included in analysis for the detected pathogen(s), regardless of 
missing stools. 
 
The primary analysis was a set of independent univariate logistic regression models each 
with an outcome of proportion of infants with incidence of ≥ 1 pathogen-specific 
diarrheal episode from week 18-52 and zinc deficiency (yes vs no) as predictor. To 
control for infections or inflammatory processes coinciding with the week 18 SZC 
measurement that may have effected SZC [14], acute phase pro-inflammatory markers 
IL-6 and CRP at week 18 were tested for possible confounding on the relationship 
between SZC and diarrheal outcomes. Spearman’s correlation was used to determine 
relationships between IL-6 and CRP with SZC (continuous). IL-6 and CRP were assessed 
for confounding in bivariate and multivariable models by > 10% change in the zinc beta 
coefficient over the primary models, and model fit was assessed by Akaike information 
criterion (AIC) [32]. 
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Given high rates of co-infection with multiple pathogens per diarrheal specimen, 
including at diarrhea-associated TAC Cq’s as well as sub-clinical carriage (TAC Cq > 
diarrhea-associated cut off), co-pathogen burden in rotavirus positive stools was 
evaluated to determine whether SZC at week 18 differed between specific combinations 
of co-pathogens. The Mann-Whitney test compared mean week 18 SZC in infants with 
rotavirus positive diarrhea plus vs minus individual co-pathogens, determined by 
presence or absence of each select enteropathogen at any positive Cq value, 0 < Cq < 35, 
in rotavirus diarrheal stools. 
 
Kaplan-Meier (KM) time-to-event analysis compared time to first viral diarrhea in zinc 
deficient vs not deficient infants, assessed for each virus separately and any viral 
diarrhea. Infants with no viral diarrhea detected from week 18-52 were censored at Day 
365. Cox proportional hazards modeling was used to assess candidate confounders of the 
KM time series results, applying the same assessment criteria described above for 
multivariable logistic regression models. Candidate confounders for the Cox proportional 
hazards model were tested for association with zinc deficiency by Chi Square for 
dichotomous predictors and Wilcoxon Rank Sum for continuous predictors. 
 
Analyses were performed in SAS software version 9.3 (SAS Institute, Cary, North 
Carolina). 
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3.3. Results 
3.3.1. Diarrhea and zinc descriptive data 
Out of 700 infants enrolled in PROVIDE, 608 completed one year of follow up per 
protocol contributing 1,773 reported diarrheal episodes between weeks 18 and 52. 
Diarrheal specimens were collected for 1,434 episodes (81%). The majority of missed 
specimens were from short duration episodes lasting 1-2 days. 88% (N=535) of infants 
had zero or only one missing specimen. Of the collected specimens, 1,367 (95%) were 
evaluable by TAC. 
 
As shown in Table 3.1., non-polio enterovirus (NPEV) and adenovirus 40/41 were the 
most prevalent pathogens in diarrheal stools and had the highest incidence in infants, 
although positive results for NPEV were based on TAC Cq < 35 in the absence of a 
published (and perhaps lower) diarrhea-associated cut-off. Of note, rotavirus accounted 
for the highest attributable incidence of diarrhea in the first year of life in PROVIDE 
based on attributable fraction calculation [1, 33]. High rates of sub-clinical carriage were 
detected for several pathogens, in particular norovirus, Campylobacter jejuni, and ST-
ETEC, which were detected in diarrheal stools but at > diarrhea-associated Cq’s in 13%, 
26% and 18% of stools respectively, in addition to the prevalences reported in Table 3.1.. 
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Table 3.1. Prevalence and incidence of pathogen-specific diarrhea, weeks 18–52 
Pathogen (diarrhea-associated Cq) 
Pathogen prevalence 
(% positive in 1,367 
diarrheal stools)a 
Percent of infants 
with ≥ 1 pathogen-specific 
diarrheal episode (N=608)a 
Rotavirus (35) 19.9 47.6 
Norovirus (27.6) 12.7 34.7 
Adenovirus 40/41 (35) 39.9 66.0 
Non-polio enterovirus (35b) 47.9 69.4 
Any viral diarrhea 78.5 82.2 
Campylobacter jejuni (19.7) 3.4 11.0 
Shigella spp/EIEC (33.1) 11.1 29.5 
ST-ETEC (26.2) 11.9 33.3 
Any bacterial diarrhea 23.1 51.1 
Cryptosporidium (29.1) 6.0 15.5 
  a Columns sum to > 100% due to co-pathogens 
    b No published diarrhea-associated Cq cut-off; 0<Cq<35 used to determine positive stools. 
   Abbreviations: spp=species; EIEC=Enteroinvasive Escherichia coli; ST-ETEC=Enterotoxigenic Escherichia coli 
 
At week 18, 577 infants had serum zinc concentration (SZC) measurements. 16.5% of the 
cohort (N=95) was at or below the threshold for zinc deficiency at week 18. The range of 
SZC was 44–173μg/dL, with a mean of 77μg/dL and median of 76μg/dL. Table 3.2. 
summarizes population characteristics for key variables, comparing infants with vs 
without zinc deficiency. 
Table 3.2. Key variables in infants with vs without zinc deficiency 
Variable Zinc deficient infants 
Non-zinc deficient 
infants P-value 
Sex (% female) 36.8 50.2 0.02 
Lack of exclusive breast feeding at week 18 (%) 52.6 50.8 0.75 
Lack of household water treatment (%) 44.2 38.2 0.27 
Birth delivery method (% cesarean) 25.3 23.2 0.67 
Any pre-week 18 diarrhea (%) 63 61 0.66 
Week 18 IL-6 inflammatory markera  64.0 (83.8) 50.5 (104.5) 0.0003 
Week 18 CRP inflammatory markera  5.8 (12.2) 2.5 (6.4) 0.01 
LA:DGLA in breast milka 20.0 (10.8) 22.0 (10.0) 0.004 
 a Mean (SD). Wilcoxon Rank Sum P-values based on log transformed data.  
All other P-values from Chi Square. 
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3.3.2. Logistic models for diarrheal outcomes and zinc deficiency 
Univariate logistic regression models tested the association between zinc deficiency and 
pathogen-specific diarrheal outcomes. As shown in Figure 3.1., the odds ratio point 
estimates and confidence intervals for each viral pathogen were similar, with increased 
odds among zinc deficient vs non-deficient infants for rotavirus OR 1.67 (95% CI 0.99 – 
2.83), norovirus OR 1.74 (95% CI 1.01 – 3.01) and adenovirus OR 1.64 (95% CI 0.94 – 
2.86). The odds of NPEV diarrhea among zinc deficient infants was highest OR 2.34 
(95% CI 1.24 – 4.41).  
 
Grouping viral pathogens into any viral diarrhea, zinc deficient infants had nearly four 
times higher odds of viral diarrhea compared to non-zinc deficient infants, OR 3.94 (95% 
CI 1.55 – 10.03, p=0.004), see Figure 3.1.. The wide confidence interval for any viral 
diarrhea was likely due the low frequency of zinc deficient infants with no viral diarrhea 
(6%). Zinc deficiency was associated with having any diarrhea OR 2.76 (95% CI 1.08 – 
7.04), regardless of etiology. Zinc deficiency did not associate with pathogen-specific 
bacterial or parasitic diarrheal outcomes. 
 
Both inflammatory biomarkers, IL-6 and CRP, correlated with zinc deficiency at week 18 
(Table 3.2.); however, neither independently associated with pathogen-specific diarrheal 
outcomes or any viral diarrhea in univariate tests. Inclusion of IL-6 in multivariable 
models did, however, improve model fit and change the zinc beta coefficients by > 10% 
for any viral diarrhea, as well as most individual pathogens. IL-6-adjusted point estimates 
and confidence intervals are shown in Figure 3.1.. 
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Figure 3.1. Odds ratios with 95% CI for univariate diarrheal outcomes in infants zinc deficient vs 
non-deficient at week 18 
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3.3.3. Kaplan-Meier analysis and Cox proportional hazards 
Figure 3.2. Kaplan-Meier curves for time to first episode of diarrhea weeks 18–52 in infants zinc 
deficient vs non-deficient at week 18 
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To determine whether zinc deficient infants were at risk for viral diarrheas earlier in the 
first year of life compared to non-zinc deficient, Kaplan-Meier analyses were done for 
each viral pathogen, as well as any viral diarrhea. On time-to-event curves, a strong 
correlation was found between zinc deficiency and time to first episode of any viral 
diarrhea, with median time diarrhea-free of 27 weeks in zinc deficient infants vs. 33 
weeks in non-deficient infants (p<0.0001). At the individual pathogen level, significant 
associations were seen between zinc deficiency and shortened time to rotavirus (log rank 
p=0.05) and NPEV diarrhea (log rank p<0.001), with no significant difference at p≤0.05 
for adenovirus or norovirus diarrhea (p=0.12 and p=0.08 respectively). Kaplan-Meier 
curves for any viral diarrhea, rotavirus and NPEV are shown in Figure 3.2.. 
 
Given strong correlations found throughout the analyses between zinc deficiency and any 
viral diarrhea, Cox proportional hazards modeling focused on this outcome. Eight 
potential risk factors were assessed for association with time to first viral diarrhea, Table 
3.3.. Adding these step-wise into a multivariable model resulted in the most parsimonious 
proportional hazards model including zinc deficiency, infant’s sex, lack of household 
water treatment, LA:DGLA ratio in mother’s breast milk, and lack of exclusive 
breastfeeding at week 18. In the final model, zinc deficient infants were at 45% greater 
risk of viral diarrhea compared to non-deficient infants (HR 1.45, 95% CI 1.13–1.87, 
p=0.003) with evidence of confounding due primarily to the addition of LA:DGLA to the 
model (18% change in zinc beta coefficient over univariate zinc model). Females had 
reduced risk of viral diarrhea compared to males (HR 0.84, 95% CI 0.69 – 1.02), and the 
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effect sizes for lack of both exclusive breastfeeding and household water treatment were 
very similar (HR 1.20, 95% CI 0.98─1.45 and 1.46 respectively). 
Table 3.3. Cox proportional hazards model with candidate confounders of association between week 
18 zinc deficiency and time to first viral diarrhea, week 18-52 
Variable Hazard ratio (95% CI) P-value 
Univariate Hazards Ratios (main effect p-values) 
Zinc deficient at week 18 1.58 (1.24 – 2.02) 0.0003 
Sex (female) 0.79 (0.65 – 0.96) 0.02 
No household water treatment 1.25 (1.03 – 1.53) 0.02 
LA:DGLA (log, continuous) 0.78 (0.62 – 0.98) 0.03 
Lack of exclusive breast feeding at week 18 1.23 (1.02 – 1.50) 0.03 
Birth delivery method (cesarean) 0.85 (0.67 – 1.07) 0.16 
Week 18 IL-6 (log, continuous) 1.05 (0.98 – 1.13) 0.20 
No rotavirus vaccine 1.07 (0.89 – 1.30) 0.47 
Multivariable Model (adjusted p-values) 
Zinc deficient at week 18 1.45 (1.13 – 1.87) 0.003 
Sex (female) 0.83 (0.68 – 1.01) 0.06 
No household water treatment 1.20 (0.98 – 1.46) 0.08 
LA:DGLA (per standard deviation of log, continuous) 0.93 (0.84 – 1.02) 0.13 
Lack of exclusive breast feeding at week 18 1.20 (0.98 – 1.45) 0.07 
 
3.3.4. Co-pathogens 
PROVIDE infants had a mean of 2.74 enteropathogens detected per diarrheal stool 
(range, 0-9 pathogens per stool at any positive Cq value). Although rotavirus (RV) was 
considered diarrhea-causing when present, 95% of RV positive stools were co-infected. 
The highest rates of co-infection were with other viruses: 40% with NPEV, 38% with 
adenovirus and 12% with norovirus, as compared to 4% – 12.5% co-infection with 
bacterial or parasitic pathogens. Despite high rates of co-infection, there was no 
difference in mean week 18 SZC between infants who had RV diarrhea +/- co-infection 
with other pathogens (all p-values for paired comparisons > 0.20, Mann-Whitney test, 
data not shown). Separate exploratory analyses showed pervasive carriage of non-ST-
ETEC E. coli spp, particularly enteroaggregative E. coli (EAEC), which was detected in 
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68% of all diarrheal stools, nearly 80% of infants, and co-infected with 71% of RV 
diarrheal stools. 
 
3.4. Discussion 
Previous work from the PROVIDE Study suggested a relationship between serum zinc 
concentration (SZC) and risk of rotavirus diarrhea in the first year of life [19]. Here, we 
have shown a broader association with a significant relationship between infant zinc 
deficiency at week 18 and risk of any viral diarrhea up to one year. While the association 
appears not to be specific to rotavirus, the trends of similar risks across viruses in the 
state of zinc deficiency may suggest a common mechanism for the protective effect of 
zinc against viral diarrhea. The association of SZC with any diarrhea in the first year also 
is likely driven by the high prevalence of viruses in the cohort: for diarrheal attributable 
incidence, five out of the top 6 diarrheal pathogens in PROVIDE are viruses [33]. These 
findings have particular importance for populations in LMICs affected by high rates of 
zinc deficiency and heavy childhood diarrheal burdens in the setting of moderate 
rotavirus vaccine efficacy and no vaccines for other viral diarrheal pathogens. 
 
Given that breast milk is the sole source of zinc nutrition for most infants in the first 
months of life, understanding the role of maternal zinc nutrition is critical to optimizing 
zinc interventions for diarrhea prevention. The extent to which zinc deficiency in mothers 
translates into zinc insufficiency in breast milk is unclear; however, associations have 
been shown between maternal plasma zinc and breast milk zinc concentration, as well as 
between maternal and infant plasma zinc [15]. Furthermore, consequences of maternal 
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zinc deficiency during gestation have been shown to persist for three generations of 
offspring [34]. While we did not directly measure mothers’ zinc, we measured the breast 
milk fatty acid ratio of linoleic acid to dihomo-γ-linoleic acid (LA:DGLA). This ratio, 
when measured in erythrocytes, correlates with individual zinc status [30, 31]. We have 
not found literature demonstrating a similar association in breast milk, however, to the 
extent this association may be found, we could hypothesize that reduced breast milk 
LA:DGLA may indicate maternal zinc deficiency which in turn may negatively impact 
zinc nutrition in infants, contributing to increased risk of viral diarrhea. The confounding 
effect shown here of LA:DGLA on the association of infant zinc deficiency with earlier 
viral diarrhea supports further investigation of this hypothesis. 
 
Once infants cease exclusive breastfeeding (EBF), other factors become important in both 
zinc nutrition and diarrheal pathogen exposures. We found infants not exclusively 
breastfed by week 18 were at significantly higher risk of earlier viral diarrhea. Only 
approximately half the PROVIDE cohort maintained EBF through week 18 [19], which 
may be particularly problematic in Bangladesh where only 40-45% of the recommended 
zinc intake for infants is met through breastfeeding plus typical complementary foods 
[35]. A longer duration of EBF in this context has greater potential to meet infants’ zinc 
requirements [36], perhaps affording better protection against viral diarrhea through the 
first year of life. Lack of household water treatment also correlated with earlier viral 
diarrhea; household-level interventions of water purification methods may improve 
diarrhea-related outcomes. 
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In terms of biologic mechanisms, zinc deficiency has been linked to dysregulated 
metabolic processes that may lead to increased risk of viral diarrhea, in particular poor 
gut epithelial repair and barrier functions. In a clear example, Chai et al (2014) 
demonstrated that piglets on a low zinc diet challenged with a porcine GI virus exhibited 
significant small intestine villous atrophy and reduced jejunal surface area compared to 
piglets on medium or high zinc diets with no post-challenge alteration in epithelial 
structure [9]. The histologic changes described in low-zinc piglets are consistent with 
environmental enteric dysfunction (EED), a pathologic spectrum of structural and 
functional abnormalities of the small intestine common in LMICs. Given the high co-
pathogen burden and high levels of systemic inflammation (IL-6) in the PROVIDE 
cohort, EED is likely prevalent [13, 37]. As hypothesized by Lindenmayer et al (2014), in 
this context, a vicious cycle of zinc deficiency and EED may contribute to increased 
susceptibility to enterpathogen infection and risk of diarrhea [12]. Future research may 
elucidate additional mechanisms linking zinc deficiency to viral diarrhea, including 
immune-mediated and microbiome-related. 
 
Limitations of the present analysis include the PROVIDE study sample size and single 
measurements of serum zinc and breast milk. Our results require validation in larger 
cohorts, ideally including serial zinc and breast milk measurements over the first year, 
temporally related to diarrheal episodes. Collection of data on maternal zinc status would 
also enhance our analysis. Interpretation of TAC data, particularly related to diarrhea 
attribution, is a work-in-progress, and assay results near the limit of detection (Cq 
30─35) may be less clinically meaningful [23]. 
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In summary, as oral rotavirus vaccines are adopted globally in national immunization 
programs, complementary interventions to address the excess burden of rotavirus 
diarrhea must be considered. The evidence provided here supports further assessment of 
targeted zinc interventions for the prevention of not only rotavirus diarrhea, but all viral 
diarrhea. Future directions should include targeted zinc supplementation trials designed 
to test the public health value of zinc supplementation, in both infants and mothers, for 
the prevention of viral diarrheas. Additionally, continued promotion of exclusive 
breastfeeding through six months and improved sanitation will contribute to a 
comprehensive approach to reducing diarrheal disease burden due to viruses. Finally, 
further interrogation of the complex biologic mechanisms relating zinc deficiency to viral 
diarrhea will contribute to enhanced interventions moving forward. 
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